WO2024061853A1 - Fluorescent probes for magl - Google Patents
Fluorescent probes for magl Download PDFInfo
- Publication number
- WO2024061853A1 WO2024061853A1 PCT/EP2023/075703 EP2023075703W WO2024061853A1 WO 2024061853 A1 WO2024061853 A1 WO 2024061853A1 EP 2023075703 W EP2023075703 W EP 2023075703W WO 2024061853 A1 WO2024061853 A1 WO 2024061853A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbonyl
- methyl
- formula
- pyrido
- phenoxy
- Prior art date
Links
- 239000007850 fluorescent dye Substances 0.000 title claims description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 165
- 238000000034 method Methods 0.000 claims abstract description 80
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 230000008569 process Effects 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- -1 benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate Chemical compound 0.000 claims description 247
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 claims description 64
- 108020002334 Monoacylglycerol lipase Proteins 0.000 claims description 64
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 26
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 20
- 150000001412 amines Chemical class 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 16
- 229910052710 silicon Inorganic materials 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 230000008878 coupling Effects 0.000 claims description 12
- 238000010168 coupling process Methods 0.000 claims description 12
- 238000005859 coupling reaction Methods 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 238000002059 diagnostic imaging Methods 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- PGZIDERTDJHJFY-UHFFFAOYSA-N 4-fluoro-7-nitro-2,1,3-benzoxadiazole Chemical compound [O-][N+](=O)C1=CC=C(F)C2=NON=C12 PGZIDERTDJHJFY-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 4
- IGHBXJSNZCFXNK-UHFFFAOYSA-N 4-chloro-7-nitrobenzofurazan Chemical compound [O-][N+](=O)C1=CC=C(Cl)C2=NON=C12 IGHBXJSNZCFXNK-UHFFFAOYSA-N 0.000 claims description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 4
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 claims description 3
- GMGNQLIBKSJBQC-UHFFFAOYSA-N 4h-pyrido[4,3-b][1,4]oxazin-3-one Chemical compound C1=NC=C2NC(=O)COC2=C1 GMGNQLIBKSJBQC-UHFFFAOYSA-N 0.000 claims description 2
- MYMPXMNUYPLJGF-UHFFFAOYSA-N propanamide 2,2,2-trifluoroacetic acid Chemical compound CCC(N)=O.OC(=O)C(F)(F)F.OC(=O)C(F)(F)F MYMPXMNUYPLJGF-UHFFFAOYSA-N 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 35
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 98
- 238000006243 chemical reaction Methods 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 28
- 239000011734 sodium Substances 0.000 description 28
- 239000002904 solvent Substances 0.000 description 27
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 26
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000543 intermediate Substances 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 229910001868 water Inorganic materials 0.000 description 20
- 239000002585 base Substances 0.000 description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 229940086542 triethylamine Drugs 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000004202 carbamide Substances 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- NJNKTPXABYMFJM-UHFFFAOYSA-N 2-(phenylmethoxycarbonylamino)ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCNC(=O)OCC1=CC=CC=C1 NJNKTPXABYMFJM-UHFFFAOYSA-N 0.000 description 8
- 239000007821 HATU Substances 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- HXRDRJKAEYHOBB-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(CO)C1 HXRDRJKAEYHOBB-UHFFFAOYSA-N 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 7
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- MWSMNBYIEBRXAL-UHFFFAOYSA-N ethyl 3-hydroxybenzoate Chemical compound CCOC(=O)C1=CC=CC(O)=C1 MWSMNBYIEBRXAL-UHFFFAOYSA-N 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- UMXXHZDEAZUQKZ-UHFFFAOYSA-N tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC11CC(O)C1 UMXXHZDEAZUQKZ-UHFFFAOYSA-N 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- PUKCUGDJEPVLPR-UHFFFAOYSA-N tert-butyl 3-(bromomethyl)azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(CBr)C1 PUKCUGDJEPVLPR-UHFFFAOYSA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- MQYZGGWWHUGYDR-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1CB1OC(C)(C)C(C)(C)O1 MQYZGGWWHUGYDR-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 5
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 238000012632 fluorescent imaging Methods 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 4
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 description 4
- XRRXRQJQQKMFBC-UHFFFAOYSA-N tert-butyl 3-hydroxyazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)C1 XRRXRQJQQKMFBC-UHFFFAOYSA-N 0.000 description 4
- YWBNYGWOYWXGKW-UHFFFAOYSA-N tert-butyl 6-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylidene]-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound CC(C)(C)OC(N1CC(C2)(CC2=CB2OC(C)(C)C(C)(C)O2)C1)=O YWBNYGWOYWXGKW-UHFFFAOYSA-N 0.000 description 4
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-PNXWREOESA-N (5z,8z,11z,14z)-2,2,3,3,4,4,5,6-octadeuterioicosa-5,8,11,14-tetraenoic acid Chemical compound OC(=O)C([2H])([2H])C([2H])([2H])C([2H])([2H])C(/[2H])=C(/[2H])C\C=C/C\C=C/C\C=C/CCCCC YZXBAPSDXZZRGB-PNXWREOESA-N 0.000 description 3
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical class C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 150000001934 cyclohexanes Chemical class 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000126 substance Chemical group 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- OHYMUFVCRVPMEY-SSDOTTSWSA-N (2r)-5-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound COC(=O)CC[C@H](C(O)=O)NC(=O)OC(C)(C)C OHYMUFVCRVPMEY-SSDOTTSWSA-N 0.000 description 2
- CPDAYCDBCSPKNF-RITPCOANSA-N (4aR,8aS)-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one Chemical compound O=C1CO[C@H]2CCNC[C@H]2N1 CPDAYCDBCSPKNF-RITPCOANSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- WJJVQUFWIDODJM-UHFFFAOYSA-N 3-(phenylmethoxycarbonylamino)propyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCCNC(=O)OCC1=CC=CC=C1 WJJVQUFWIDODJM-UHFFFAOYSA-N 0.000 description 2
- SPNJWSMCGHDXEQ-SCSAIBSYSA-N 3-[(4R)-2-oxo-1,3-oxazolidin-4-yl]propanoic acid Chemical compound OC(CC[C@H](CO1)NC1=O)=O SPNJWSMCGHDXEQ-SCSAIBSYSA-N 0.000 description 2
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 2
- CIYUDMUBYRVMLP-UHFFFAOYSA-N 3-oxo-4h-1,4-benzoxazine-6-carboxylic acid Chemical compound O1CC(=O)NC2=CC(C(=O)O)=CC=C21 CIYUDMUBYRVMLP-UHFFFAOYSA-N 0.000 description 2
- CVDNOPQSKSZLNU-UHFFFAOYSA-N 5-(phenylmethoxycarbonylamino)pentyl 4-methylbenzenesulfonate Chemical compound S(=O)(=O)(OCCCCCNC(=O)OCC1=CC=CC=C1)C1=CC=C(C)C=C1 CVDNOPQSKSZLNU-UHFFFAOYSA-N 0.000 description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- XSUXDJHVNPNNFJ-UHFFFAOYSA-N OBOC=C Chemical class OBOC=C XSUXDJHVNPNNFJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229940005667 ethyl salicylate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 238000010859 live-cell imaging Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- SRVJJSKMYILGAM-QMMMGPOBSA-N methyl (4s)-5-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound COC(=O)CC[C@@H](CO)NC(=O)OC(C)(C)C SRVJJSKMYILGAM-QMMMGPOBSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XPDIKRMPZNLBAC-UHFFFAOYSA-N tert-butyl 3-iodoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(I)C1 XPDIKRMPZNLBAC-UHFFFAOYSA-N 0.000 description 2
- FZOPVLTXCLJRJV-UHFFFAOYSA-N tert-butyl 6-phenylmethoxy-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC11CC(OCC=2C=CC=CC=2)C1 FZOPVLTXCLJRJV-UHFFFAOYSA-N 0.000 description 2
- NQHGYUZNWXIZID-UHFFFAOYSA-N tert-butyl 7-hydroxy-2-azaspiro[3.5]nonane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CCC(O)CC2 NQHGYUZNWXIZID-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- CMIBUZBMZCBCAT-HOTGVXAUSA-N (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HOTGVXAUSA-N 0.000 description 1
- LOVPHSMOAVXQIH-UHFFFAOYSA-M (4-nitrophenyl) carbonate Chemical compound [O-]C(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-M 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- YAXWOADCWUUUNX-UHFFFAOYSA-N 1,2,2,3-tetramethylpiperidine Chemical compound CC1CCCN(C)C1(C)C YAXWOADCWUUUNX-UHFFFAOYSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 1
- RCRCTBLIHCHWDZ-DOFZRALJSA-N 2-arachidonoylglycerol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-DOFZRALJSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane Substances CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XBROEIKBUIJUKW-RJYAGPCLSA-N 4-[[[(3s)-6,7-dimethoxy-2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-1h-isoquinoline-3-carbonyl]amino]methyl]cyclohexane-1-carboxylic acid Chemical compound O=C([C@@H]1CC=2C=C(C(=CC=2CN1C(=O)OC(C)(C)C)OC)OC)NCC1CCC(C(O)=O)CC1 XBROEIKBUIJUKW-RJYAGPCLSA-N 0.000 description 1
- ZCVAGTPWBAZXAL-UHFFFAOYSA-N 4-nitro-2,1,3-benzoxadiazole Chemical compound [O-][N+](=O)C1=CC=CC2=NON=C12 ZCVAGTPWBAZXAL-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 238000006677 Appel reaction Methods 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 101100054570 Caenorhabditis elegans acn-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000007295 Wittig olefination reaction Methods 0.000 description 1
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 description 1
- DACWQSNZECJJGG-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CN=C21 DACWQSNZECJJGG-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- BCXRVLRZEXVMGD-RXMQYKEDSA-N methyl 3-[(4R)-2-oxo-1,3-oxazolidin-4-yl]propanoate Chemical compound COC(CC[C@H](CO1)NC1=O)=O BCXRVLRZEXVMGD-RXMQYKEDSA-N 0.000 description 1
- BCXRVLRZEXVMGD-YFKPBYRVSA-N methyl 3-[(4S)-2-oxo-1,3-oxazolidin-4-yl]propanoate Chemical compound COC(=O)CC[C@H]1COC(=O)N1 BCXRVLRZEXVMGD-YFKPBYRVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- DVUBDHRTVYLIPA-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CC=C21 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- HVUXNJRKIXTEJG-UHFFFAOYSA-N spiro[1,2-dihydroindole-3,1'-cyclopropane] Chemical group C1CC11C2=CC=CC=C2NC1 HVUXNJRKIXTEJG-UHFFFAOYSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JVIDPFGQYMFQDZ-JVHMLUBASA-N tert-butyl (1s,5r)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)C[C@H]2C(CO)[C@H]21 JVIDPFGQYMFQDZ-JVHMLUBASA-N 0.000 description 1
- YEEGEOMIWYMLIL-UHFFFAOYSA-N tert-butyl 3-(phenoxymethyl)azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1COC1=CC=CC=C1 YEEGEOMIWYMLIL-UHFFFAOYSA-N 0.000 description 1
- ONUHNLXBKPXAAV-UHFFFAOYSA-N tert-butyl 3-(phenylmethoxymethyl)azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1COCC1=CC=CC=C1 ONUHNLXBKPXAAV-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B11/00—Diaryl- or thriarylmethane dyes
- C09B11/04—Diaryl- or thriarylmethane dyes derived from triarylmethanes, i.e. central C-atom is substituted by amino, cyano, alkyl
- C09B11/10—Amino derivatives of triarylmethanes
- C09B11/24—Phthaleins containing amino groups ; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
- C09B23/04—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups one >CH- group, e.g. cyanines, isocyanines, pseudocyanines
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/10—The polymethine chain containing an even number of >CH- groups
- C09B23/105—The polymethine chain containing an even number of >CH- groups two >CH- groups
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B51/00—Nitro or nitroso dyes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/918—Carboxylic ester hydrolases (3.1.1)
- G01N2333/92—Triglyceride splitting, e.g. by means of lipase
Definitions
- the present invention relates to organic compounds useful as fluorescent probes for monoacylglycerol lipase (MAGL).
- MIML monoacylglycerol lipase
- Background of the Invention Fluorescent imaging probes have emerged as high resolution tools to investigate localization, e.g. expression levels and protein distribution in health and disease, structure, dynamics and function of proteins in living cells (L. A. Stoddart, L. E. Kilpatrick, S. J. Briddon, S. J. Hill, Neuropharmacology 2015, 98, 48-57).
- Such probes can e.g.
- fluorescent imaging probes allow for real-time monitoring of ligand-receptor interactions and protein visualization with high spatiotemporal precision (A. J. Vernall, S. J. Hill, B. Kellam, Br. J. Pharmacol.2014, 171, 1073–1084; C. Iliopoulos-Tsoutsouvas, R. N. Kulkarni, A. Makriyannis, S. P. Nikas, Expert Opin. Drug Discov.2018, 13, 933–947).
- Fluorescent imaging probes can also be useful to support the translation of preclinical pharmacological animal data to clinics and can be applied for dose selection in humans. They can e.g. be used as markers of target engagement via the generation of ex vivo quantitative receptor binding data in whole blood. Depending on the respective application, a fluorescent imaging probe needs to match specific criteria, including affinity, selectivity and specificity for the respective target, favorable photophysical properties, and applicability across distinct techniques and cell types.
- the present invention provides a compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, wherein A, L, n, and R 1 to R 3 are as defined herein.
- the present invention provides processes for manufacturing said compounds of formula (I) or (II).
- the present invention provides a compound of formula (I) or (II) as described herein, when manufactured according to the processes described herein.
- the present invention provides the use of a compound of formula (II) described herein for the preparation of a fluorescent probe of formula (I) described herein.
- the present invention provides a method of studying monoacylglycerol lipase (MAGL) occupancy, comprising contacting MAGL with a compound of formula (I) described herein.
- the present invention provides a method of diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal, comprising contacting MAGL with a compound of formula (I) described herein.
- the present invention provides a method of generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data, comprising contacting MAGL with a compound of formula (I) described herein.
- heteroaryl refers to a mono- or multivalent, monocyclic, bicyclic or tricyclic, preferably bicyclic ring system having a total of 5 to 14 ring members, preferably, 5 to 12 ring members, and more preferably 5 to 10 ring members, wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms.
- heteroaryl refers to a 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. Most preferably, “heteroaryl” refers to a 5-10 membered heteroaryl comprising 1 to 2 heteroatoms independently selected from O, S and N.
- heteroaryl examples include spiro[cyclopropane-1,3'- indoline] (e.g., spiro[cyclopropane-1,3'-indoline]-1'-yl), 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazin-2-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, indol-1-yl, 1H-indol-2-yl, 1H-indol-3-yl, 1H-indol-4-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1H-indol-7-yl, 1,2-benzoxazol-3-yl, 1,2-benzoxazol-4-yl, 1,2-benzoxazol-5-yl, 1,2-benzoxazol-6-yl
- aryl refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of 6 to 10 ring members (“C6-C10-aryl”), wherein at least one ring in the system is aromatic.
- Some non-limiting examples of aryl include phenyl and 9H-fluorenyl (e.g.9H-fluoren-9-yl).
- a particularly preferred, yet non-limiting example of aryl is phenyl.
- alkyl refers to a mono- or multivalent, e.g., a mono- or bivalent, linear or branched saturated hydrocarbon group of 1 to 12 carbon atoms.
- the alkyl group contains 1 to 6 carbon atoms, e.g., 1, 2, 3, 4, 5, or 6 carbon atoms (“C1-C6-alkyl”). In other embodiments, the alkyl group contains 1 to 3 carbon atoms, e.g., 1, 2 or 3 carbon atoms.
- Some non-limiting examples of alkyl include methyl, ethyl, propyl, 2-propyl (isopropyl), n-butyl, iso-butyl, sec-butyl, tert-butyl, and 2,2- dimethylpropyl.
- a particularly preferred, yet non-limiting example of alkyl is methyl.
- alkoxy refers to an alkyl group, as previously defined, attached to the parent molecular moiety via an oxygen atom. Unless otherwise specified, the alkoxy group contains 1 to 12 carbon atoms. In some preferred embodiments, the alkoxy group contains 1 to 6 carbon atoms (“C1-C6-alkoxy”). In other embodiments, the alkoxy group contains 1 to 4 carbon atoms. In still other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non-limiting examples of alkoxy groups include methoxy, ethoxy, n- propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy. A particularly preferred, yet non-limiting example of alkoxy is methoxy.
- alkoxycarbonyl refers to an alkoxy group, as previously defined, attached to the parent molecular moiety via a carbonyl group.
- the alkoxy moiety of the alkoxycarbonyl group contains 1 to 6 carbon atoms (“C1-C6- alkoxycarbonyl”).
- the alkoxy group contains 1 to 4 carbon atoms.
- the alkoxy group contains 1 to 3 carbon atoms.
- alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, n- propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl and tert- butoxycarbonyl.
- alkoxy is tert- butoxycarbonyl.
- pharmaceutically acceptable salt refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable.
- the salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like.
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like
- organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid,
- salts may be prepared by addition of an inorganic base or an organic base to the free acid.
- Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like.
- Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N- ethylpiperidine, piperidine, polyimine resins and the like.
- Particular pharmaceutically acceptable salts of compounds of formula (I) are hydrochloride salts.
- the compounds of formula (I) can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereioisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
- the asymmetric carbon atom can be of the "R” or "S” configuration.
- the abbreviation “MAGL” refers to the enzyme monoacylglycerol lipase.
- the terms “MAGL” and “monoacylglycerol lipase” are used herein interchangeably.
- the present invention provides a compound of formula (I) or (II) A A n (I) (II) or a pharmaceutically acceptable salt thereof, wherein: R 1 is selected from: ; wherein a wavy line indicates the point of attachment of R 1 to the remainder of formula (I) or (II); R 2 is selected from:
- a wavy line indicates the point of attachment of R 2 to the remainder of formula (I); p is 1 or 2; is selected from hydrogen and methyl; W is selected from methyl, phenyl, , , , , , ; wherein Ar is C6-C10-aryl or 5- to 14-membered heteroaryl; is selected from O, S, Si(CH 3 ) 2 , and CH 2 ; and is selected from OH, NH 2 , N(CH 3 ) 2 , N(CD 3 ) 2 , and azetidin-1-yl; R 3 is selected from hydrogen, C1-C6-alkoxycarbonyl and C1-C6-alkoxycarbonyl- NH-C 1 -C 6 -alkyl-NH-C(O)–; (ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of
- the present invention provides a compound of formula (I) or (II) as described herein or a pharmaceutically acceptable salt thereof, wherein: in Formula (I), R 1 is selected from: , , , and ; wherein a wavy line indicates the point of attachment of R 1 to the remainder of formula (I); in Formula (II), R 1 is selected from: wherein a wavy line indicates the point of attachment of R 1 to the remainder of formula (II); R 2 is selected from:
- a wavy line indicates the point of attachment of R 2 to the remainder of formula (I); p is 1 or 2; V is selected from hydrogen and methyl; , Ar is C 6 -C 10 -aryl or 5- to 14-membered heteroaryl; X is selected from O, S, Si(CH3)2, and CH2; and Y is selected from OH, NH 2 , N(CH 3 ) 2 , N(CD 3 ) 2 , and azetidin-1-yl; R 3 is selected from hydrogen, C1-C6-alkoxycarbonyl and C1-C6-alkoxycarbonyl- NH-C 1 -C 6 -alkyl-NH-C(O)–; A is: (ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I) or (II),
- the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , A, L, and n are as defined herein. In one aspect, the present invention provides a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 , A, and L are as defined herein. In one embodiment, the present invention provides a compound of formula (I) or (II) as described herein, or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from: wherein a wavy line indicates the point of attachment of R 1 to the remainder of formula (I).
- the present invention provides a compound of formula (I) or (II) as described herein, or a pharmaceutically acceptable salt thereof, wherein R 1 is ; wherein a wavy line indicates the point of attachment of R 1 to the remainder of formula (I). In one embodiment, the present invention provides a compound of formula (I) or (II) as described herein, or a pharmaceutically acceptable salt thereof, wherein R 1 is ; wherein a wavy line indicates the point of attachment of R 1 to the remainder of formula (I).
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is: (i) X is CH; and L is selected from –CH2– and –CH2O–; or (ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I).
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is: ; (i) X is CH and L is –CH2–; or (ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I).
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is: X is CH; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I).
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I).
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is and L is –CH 2 –; wherein X is CH; a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I).
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R 2 is selected from: , a wavy line indicates the point of attachment of R 2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH 3 ) 2 ; and Y is N(CH 3 ) 2 ; and n is an integer selected from 1, 2, and 4.
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R 2 is selected from: , , , and p ; wherein: a wavy line indicates the point of attachment of R 2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; and n is an integer selected from 1, 2, and 4.
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R 2 is selected from:
- a wavy line indicates the point of attachment of R 2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; and n is an integer selected from 1 and 4.
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: 2 R is ; wherein: the wavy line indicates the point of attachment of R 2 to the remainder of formula (I); and n is an integer selected from 1 and 4.
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R 2 is ; wherein: the wavy line indicates the point of attachment of R 2 to the remainder of formula (I); V is methyl; W is methyl; and n is an integer selected from 1 and 4.
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R 2 ; wherein: the wavy line indicates the point of attachment of R 2 to the remainder of formula (I); X is selected from O and Si(CH 3 ) 2 ; Y is N(CH3)2; and n is an integer selected from 1 and 4.
- the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R 2 wherein: the wavy line indicates the point of attachment of R 2 to the remainder of formula (I); p is 1; and n is an integer selected from 1 and 4.
- the present invention provides a compound of formula (II) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is: (i) and L is selected from –OCH2–, –CH2OCH2–, and –O–; or (ii) and L is –CH2O–; wherein X is CH; wherein a wavy line indicates the point of attachment to L; and an asterisk indicates the point of attachment to the carbonyl group of formula (II).
- the present invention provides a compound of formula (I) as described herein, wherein: R 1 is selected from: ; wherein a wavy line indicates the point of attachment of R 1 to the remainder of formula (I); R 2 is selected from: , , , p , and ; wherein: a wavy line indicates the point of attachment of R 2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; A is: (ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment to L; and an asterisk indicates the point of attachment to the carbonyl group of formula (I); and n is an
- the present invention provides a compound of formula (I) as described herein, wherein: R 1 is selected from: wherein a wavy line indicates the point of attachment of R 1 to the remainder of formula (I); R 2 is selected from: a wavy line indicates the point of attachment of R 2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; A is: (ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I); and n is an integer selected from 1, 2, and 4.
- the present invention provides a compound of formula (I) as described herein, wherein: wherein a wavy line indicates the point of attachment of R 1 to the remainder of formula (I); R 2 is selected from: , , , and p ; wherein: a wavy line indicates the point of attachment of R 2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; A is: X is CH; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I); and n is an integer selected from 1 and 4.
- the present invention provides a compound of formula (I) or (II) as described herein, wherein the compound of formula (I) or (II) is selected from: benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((2-((4aR,8aS)-3-oxooctahydro
- the present invention provides a compound of formula (I) as described herein, wherein the compound of formula (I) is selected from: benzyl (6-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)hexyl)carbamate; benzyl (2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)ethyl)carbamate; benzyl (5-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azas
- the present invention provides a compound of formula (II) as described herein, wherein the compound of formula (II) is selected from: benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[
- the present invention provides pharmaceutically acceptable salts of the compounds according to formula (I) as described herein.
- the present invention provides compounds according to formula (I) as described herein as free bases.
- Processes of Manufacturing The preparation of compounds of formula (I) or (II) of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following general schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those persons skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein, unless indicated to the contrary.
- protective groups as described e.g., in “Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wutts, 5th Ed., 2014, John Wiley & Sons, N.Y.
- Such protective groups can be removed at a later stage of the synthesis using standard methods described in the literature.
- compounds of formula (I) or (II) can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art e.g., chiral HPLC, chiral SFC or chiral crystallization. Racemic compounds can e.g., be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes by specific chromatographic methods using either a chiral adsorbent or a chiral eluent. It is equally possible to separate starting materials and intermediates containing stereogenic centers to afford diastereomerically/enantiomerically enriched starting materials and intermediates.
- reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity, the sequence of reaction steps can be freely altered. If starting materials or intermediates are not commercially available or their synthesis not described in literature, they can be prepared in analogy to existing procedures for close analogues or as outlined in the experimental section.
- amines derivatives 1 carry a suitable nitrogen protecting group “PG” at the end of the alkane chain, such as benzyloxycarbonyl (Cbz) carbamate, and an orthogonal nitrogen protecting group “PG 1 ” at the cyclic amine, such as a tert-butyloxycarbonyl (Boc) carbamate.
- PG nitrogen protecting group
- Removal of the protective group PG 1 intermediates 1, applying methods known in the art e.g., a Boc group using TFA in DCM at temperatures between 0 °C and room temperature, a Cbz group using hydrogen in the presence of a suitable catalyst such as Pd or Pd(OH)2 on charcoal in a suitable solvent such as MeOH, EtOH, EtOAc or mixtures thereof and as described for example in “Protective Groups in Organic Chemistry” by T.W. Greene and P.G.M.
- urea forming reagent such as bis(trichloromethyl) carbonate using a suitable base and solvent such as, e.g. sodium bicarbonate in DCM, to furnish compounds 3, including compunds of the formula Ia (step a1).
- urea forming reagents include but are not limited to phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate or 1,1’-carbonyldiimidazole.
- Amide couplings of this type can be accomplished by using one of the well-known coupling reagents such as DCC, HATU, EDCI, HOBt, TBTU, T3P, etc. and a base like Huenig’s base, triethylamine or DMAP in a suitable solvent like N,N-dimethylformamide, DMA, DCM or 1-4-dioxane, preferably between 0 °C and room temperature.
- a suitable solvent like N,N-dimethylformamide, DMA, DCM or 1-4-dioxane
- Amide couplings of this type can be accomplished by using one of the well-known coupling reagents such as, DCC, HATU, EDCI, HOBt, TBTU, T3P, etc. and a base like Huenig’s base, triethyl amine or DMAP in a suitable solvent solvent like N,N-dimethylformamide, DMA, DCM or dioxane, preferably between 0 °C and room temperature.
- a suitable solvent solvent like N,N-dimethylformamide, DMA, DCM or dioxane
- a fluorescent label containing an N- hydroxisuccinimide (NHS) activated ester can be reacted with 4 to afford compounds of the formula Ib in the presence of a suitable base, such as N,N-diisopropylethylamine (DIPEA), 2,6-lutidine, etc. in a suitable solvent such as DCM, THF, ACN, DMF, or dioxane, preferably between 0 °C and room temperature.
- a suitable base such as N,N-diisopropylethylamine (DIPEA), 2,6-lutidine, etc.
- DIPEA N,N-diisopropylethylamine
- a suitable solvent such as DCM, THF, ACN, DMF, or dioxane, preferably between 0 °C and room temperature.
- amines 4 can be reacted in a nucleophic aromatic substitution with 4-chloro-7-nitrobenz-2-oxa-1,3-diazole (CAS RN 10199-89-0) or 4-fluoro-7-nitrobenz-2- oxa-1,3-diazole (CAS RN 29270-56-2), e.g. in the presence of a base such as triethylamine in a solvent as MeOH, preferably between 0 °C and room temperature (step c).
- amine derivatives 1 in which “PG” is a fluorescent label can be converted directly to compounds of formula Ib according to step a.
- Protected amines 1 and their amine 2a or carboxylic acid 2b counterparts are either commercially available or can be prepared according to literature methods or as depicted below.
- Intermediates of type 1, such as intermediates 1a and 1b can be prepared by a variety of conditions, which may be exemplified by the general synthetic procedure outlined in Scheme 2.
- Scheme 2 Intermediates 5, 6 and 11 are either commercially available or can be prepared according to literature methods.
- the functional hydroxyl group in 5 and 11 can be utilized to attach alkane chain derivatives of the type 6, where “LG” is a suitable leaving group such as, but not limited to, methanesulfonic ester (OMs), p-toluensulfonic ester (OTs), bromine, iodide, via nucleophilic substitution (S N ) reactions in the presence of a suitable base (e.g. Cs 2 CO 3 , K2CO3), in a suitable solvent (e.g. DMF) preferably at temperatures between room temperature and 80 °C, to yield compounds 7 and 12, respectively (step d).
- a suitable base e.g. Cs 2 CO 3 , K2CO3
- a suitable solvent e.g. DMF
- Intermediates of the type 7 and 12 can also be obtained by other etherification reactions according to literature methods, or e.g.
- Benzoic esters of type 7 can be transformed to their corresponding benzylic alcohols 8 by treatment with a suitable reducing agent, such as LiAlH 4 , LiBH 4 , diisobutylaluminium hydride (DIBAL-H), in a suitable solvent such as toluene, preferably at temperatures between -78° and 0° C (step e).
- a suitable reducing agent such as LiAlH 4 , LiBH 4 , diisobutylaluminium hydride (DIBAL-H)
- DIBAL-H diisobutylaluminium hydride
- Benzyl alcohols 8 can be converted into their benzyl bromide analogues 9 by reactions described in literature, such as Appel reaction with CBr4 and PPh3 or using PBr3, in a suitable solvent such as DCM, preferably at temperatures between 0 and 25 °C (step f).
- Molecules of the type 1a can be obtained by reacting benzyl bromides 9 with alcohols 10 in nucleophilic substitution reaction in presence of a suitable base, such as KOtBu, in a suitable solvent, such as THF, preferably at temperature between room temperature and 80 °C (step g).
- Intermediates of the type 1b can be readily accessed via cross-coupling reactions with suitable building blocks, such as vinyl boronic esters 13, in the presence of a suitable base such as K2CO3, a suitable water- containing solvent mixture such as water/dioxane, with a transition metal catalyst such as, but not limited to, Pd(dppf)Cl2, preferably at temperatures between 25 and 100 °C (step h).
- suitable building blocks such as vinyl boronic esters 13
- a suitable base such as K2CO3
- a suitable water- containing solvent mixture such as water/dioxane
- Pd(dppf)Cl2 transition metal catalyst
- hydrolysis of vinyl boronates 13 by methods known to those skilled in the art, such as treatment with ammonium acetate buffered water/acetone mixtures and sodium periodate, can be conducted as an individual step, and subsequent (step h) can be conducted in absence of water.
- Vinyl boronic esters 13 are either commercially available or can be prepared according to literature methods or as depicted below.
- Vinyl boronates 13 e.g. vinyl boronic acid pinacol ester
- Phenol ester derivatives 16 can be reacted via nucleophilic substitution with intermediates 15 to afford ether intermediates 17, in analogy to the methods described for the transformation of 5 to 7 in scheme 2 (step d).
- Compounds of the type IIa can be obtained from 17 in analogy to the transformation of 1 to 3 in scheme 1 (step a).
- Compounds with the formula IIb can be obtained from reaction of IIa with amines 18 under amide coupling conditions, eg. by using one of the well-known coupling reagents such as, DCC, HATU, EDCI, HOBt, TBTU, T3P, etc.
- step l treating benzyl bromide 19 with alcohols of the type 10 (see above) under nucleophilic substitution conditions, in the presence of a suitable base, such as sodium hydride (NaH) and a suitable solvent such as DMF/DCM mixture, preferably at temperatures between 0 and 25 °C affords ether intermediates 20 (step l).
- a suitable base such as sodium hydride (NaH) and a suitable solvent such as DMF/DCM mixture, preferably at temperatures between 0 and 25 °C affords ether intermediates 20 (step l).
- the present invention provides a process of manufacturing the compounds of formula (I) as described herein, comprising reacting an amine 4, wherein A, L, R 1 , and n are as defined herein, with: (a) a fluorescent label containing a carboxylic acid moiety in the presence of a coupling reagent and a base; or (b) a fluorescent label containing an N-hydroxisuccinimide (NHS) activated ester in the presence of a base; or (c) 4-chloro-7-nitrobenz-2-oxa-1,3-diazole or 4-fluoro-7-nitrobenz-2-oxa-1,3- diazole in in the presence of a base; to afford said compound of formula (I).
- said fluorescent label containing a carboxylic acid moiety in reaction (a) is selected from: , , p , and p ; wherein: X, Y, V, W, and p are as defined herein.
- said coupling reagent in reaction (a) is selected from DCC, HATU, EDCI, HOBt, TBTU, and T3P.
- said base in reaction (a) is selected from Huenig’s base, triethyl amine, and DMAP.
- said reaction (a) is conducted in a suitable solvent solvent, preferably in a solvent selected from N,N-dimethylformamide, DMA, DCM, and dioxane.
- said fluorescent label containing an N-hydroxisuccinimide (NHS) activated ester in reaction (b) is selected from: , , p , and p ; wherein: X, Y, V, W, and p are as defined herein.
- said base in reaction (b) is selected from N,N-diisopropylethylamine (DIPEA) and 2,6-lutidine.
- said reaction (b) is conducted in a suitable solvent solvent, preferably in a solvent selected from DCM, THF, ACN, DMF, and dioxane.
- said base in reaction (c) is triethylamine.
- said reaction (c) is conducted in a suitable solvent solvent, preferably in methanol.
- the present invention provides a compound of formula (I) or (II) as described herein, when manufactured according to any one of the processes described herein.
- MAGL Inhibitory Activity Compounds were profiled for MAGL inhibitory activity by determining the enzymatic activity by following the hydrolysis of the natural substrate 2-arachidonoylglycerol (2-AG) resulting in arachidonic acid, which can be followed by mass spectrometry. This assay is hereinafter abbreviated “2-AG assay”. The 2-AG assay was carried out in 384 well assay plates (PP, Greiner Cat# 784201) in a total volume of 20 ⁇ L.
- Compound dilutions were made in 100% DMSO (VWR Chemicals 23500.297) in a polypropylene plate in 3-fold dilution steps to give a final concentration range in the assay from 12.5 ⁇ M to 0.8 pM.0.25 ⁇ L compound dilutions (100% DMSO) were added to 9 ⁇ L MAGL in assay buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka, 03690-100 mL), 0.01% (v/v) Tween. After shaking, the plate was incubated for 15 min at RT. To start the reaction, 10 ⁇ L 2-arachidonoylglycerol in assay buffer was added.
- the final concentrations in the assay was 50 pM MAGL and 8 ⁇ M 2- arachidonoylglyerol. After shaking and 30 min incubation at RT, the reaction was quenched by the addition of 40 ⁇ L of ACN containing 4 ⁇ M of d8-arachidonic acid. The amount of arachidonic acid was traced by an online SPE system (Agilent Rapidfire) coupled to a triple quadrupole mass spectrometer (Agilent 6460). A C18 SPE cartridge (G9205A) was used in an ACN/water liquid setup.
- the mass spectrometer was operated in negative electrospray mode following the mass transitions 303.1 259.1 for arachidonic acid and 311.1 267.0 for d8-arachidonic acid.
- the activity of the compounds was calculated based on the ratio of intensities [arachidonic acid / d8-arachidonic acid].
- Table 1 The compounds of formula (I) are fluorescent imaging probes with high affinity for MAGL. They may thus be used as high resolution tools to investigate localization, e.g. expression levels and protein distribution in health and disease, structure, dynamics and function of MAGL in living cells. They may also be applied e.g. in flow cytometry fluorescence-activated cell sorting (FACS) experiments or cellular trafficking studies using confocal live cell imaging.
- FACS flow cytometry fluorescence-activated cell sorting
- the present invention provides a compound of formula (I) described herein, for use in monoacylglycerol lipase (MAGL) occupancy studies.
- the present invention provides a compound of formula (I) described herein, for use in diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal.
- the present invention provides a compound of formula (I) described herein, for use in generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data.
- the present invention provides using a compound of formula (I) described herein in monoacylglycerol lipase (MAGL) occupancy studies.
- the present invention provides using a compound of formula (I) described herein in diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal.
- the present invention provides using a compound of formula (I) described herein for generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data.
- the present invention provides a method of studying monoacylglycerol lipase (MAGL) occupancy, comprising contacting MAGL with a compound of formula (I) described herein.
- the present invention provides a method of diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal, comprising contacting MAGL with a compound of formula (I) described herein.
- the present invention provides a method of generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data, comprising contacting MAGL with a compound of formula (I) described herein.
- the compounds of formula (II) are useful synthetic intermediates for the preparation of the fluorescent probes of formula (I).
- the present invention provides the use of a compound of formula (II) described herein for the preparation of a fluorescent probe of formula (I) described herein.
- Step e Benzyl (2-(2-(hydroxymethyl)phenoxy)ethyl)carbamate Ester ethyl 2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzoate (1.15 g, 3.35 mmol) was dissolved in toluene (11.2 mL) under N 2 atmosphere at 0 °C, and a 1M DIBAL in DCM solution (15.1 mL, 15.1 mmol) was added dropwise. The reaction mixture was stirred at 0 °C until completion (1.5 h, TLC monitoring). The reaction was quenched by diluting with DCM (20 mL) and dropwise addition of AcOH (0.86 mL, 15.1 mmol).
- Step f Benzyl (2-(2-(bromomethyl)phenoxy)ethyl)carbamate
- benzyl (2-(2-(hydroxymethyl)phenoxy)ethyl)carbamate 795 mg, 2.64 mmol
- DCM dimethylethyl
- CBr4 (1.00 g, 3.04 mmol) was added followed by PPh3 (796 mg, 3.04 mmol, 1.5 M solution in DCM).
- the reaction mixture was stirred at r.t. until completion (10 min, TLC monitoring).
- the reaction was quenched by diluting with DCM (30 mL), extracted with aq. sat.
- Step g tert-Butyl 3-(((2-(2- tert-Butyl 3-(hydroxymethyl)azetidine-1-carboxylate (CAS RN 142253-56-3, 196 mg, 1.05 mmol) was dissolved in anhydrous THF (7 mL) at 0 °C, KOtBu (118 mg, 1.05 mmol) was added, and the mixture was stirred for 5 min. Next, bromine derivative benzyl (2-(2- (bromomethyl)phenoxy)ethyl)carbamate (254.9 mg, 0.70 mmol) was dissolved in anhydrous THF (1.5 mL) and added dropwise to the reaction mixture. The mixture was then allowed to warm up to r.t.
- Step a1 Benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate 1.
- reaction mixture was stirred at room temperature for 2 h. Then, the amine nucleophile from step 1 2,2,2-trifluoroacetate salt of 3-(((2-(2- (((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)azetidine was dissolved in ACN (0.5 mL) and added dropwise to the reaction mixture. The reaction mixture was heated to 50 °C and stirred at that temperature for 2.5 h. The reaction was quenched by diluting with DCM (5.00 mL), extracted with aq. sat. NaHCO 3 (2.00 mL) and washed with brine (2.00 mL). The organic layer was dried over MgSO4, filtrated and concentrated under reduced pressure.
- Example 15 Benzyl (2-(2-(((7-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-7-azaspiro[3.5]nonan-2-yl)oxy)methyl)phenoxy)ethyl)carbamate
- Step g tert-Butyl 2-((2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)-7- azaspiro[3.5]nonane-7-carboxylate (BB 13)
- benzyl (2-(2- (bromomethyl)phenoxy)ethyl)carbamate was reacted with tert-butyl 6- hydroxy-2-azaspiro[3.3]
- Step a1 Benzyl (2-(2-(((7-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-7-azaspiro[3.5]nonan-2-yl)oxy)methyl)phenoxy)ethyl)carbamate 1. Boc deprotection.
- step (1) tert- Butyl 2-((2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)-7-azaspiro[3.5]nonane-7- carboxylate (BB 13) (52.5 mg, 0.10 mmol) was dissolved in DCM (0.7 mL) at 0 °C and TFA (0.11 mL, 1.40 mmol) was added. The reaction mixture was stirred at that temperature until Boc deprotection was complete (30 min, LC-MS monitoring). The reaction was diluted with toluene (3.00 mL), and coevaporated with toluene (3.00 mL) under reduced pressure twice.
- Example 17 Benzyl (R)-(2-(2-((((1-(3-(2-oxooxazolidin-4-yl)propanoyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate Synthesis of the building block: 3-[(4R)-2-Oxooxazolidin-4-yl]propanoic acid (3 steps) Step 1) Methyl (S)-4-((tert-butoxycarbonyl)amino)-5-hydroxypentanoate To a solution of (R)-2-((tert-butoxycarbonyl)amino)-5-methoxy-5-oxopentanoic acid (1 g, 3.83 mmol, CAS: 76379-01-6) in THF (15 mL) at -10 °C was added N-methylmorpholine (421 ⁇ L,
- Step 2 Methyl (R)-3-(2-oxooxazolidin-4-yl)propanoate
- methyl (S)-4-((tert-butoxycarbonyl)amino)-5-hydroxypentanoate 690 mg, 2.79 mmol, 1.0 equiv
- THF 8.8 mL
- thionyl chloride 611 ⁇ L, 8.37 mmol,3.0 equiv
- Step a2 (R)-(2-(2-((((1-(3-(2-oxooxazolidin-4-yl)propanoyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate
- R)-3-(2-oxooxazolidin-4-yl)propanoic acid (12.7 mg, 0.08 mmol) was dissolved in THF/ACN 1:1 (1.60 mL) and then DIPEA (42.0 ⁇ L, 0.24 mmol) followed by HATU (36.5 mg, 96.0 ⁇ mol) were added.
- Example 18 Benzyl (2-(2-(((1-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate
- step a2 tert-butyl 3-(((2-(2- (((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carboxylate BB1 was reacted with 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylic acid (CAS RN: 134997-87-8) to afford the title compound (22.3 mg, 0.0.41 mmol, 50%).
- the starting material benzyl (2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)ethyl)carbamate (Example 13, 16.0 mg, 0.03 mmol) was dissolved in the previously prepared solvent mixture and purged with N 2 for 10 min. Next, Palladium on Carbon (10 mol%) was added to the mixture and further purged with N 2 for additional 15 min. Using a H 2 -filled balloon, the reaction was then carried with constant bubbling of H 2 through the solution until completion (LC-MS monitoring).
- Solvent mixture levels were kept at 1-2 mL by adding small amounts of the previously prepared N2-purged solvent mixture when needed. Palladium on carbon was removed from reaction the mixture by filtration with a PTFE syringe filter (pore size: 0.45 ⁇ m) using ACN and water to wash the filter. The crude was lyophilized and the obtained title compound was used in next step (step c) without further purification.
- Step c 2-(6-(2-(2-((7-nitro-1l2,3l2-benzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)benzyl)-2- azaspiro[3.3]heptane-2-carbonyl)-7-oxa-2,5-diazaspiro[3.4]octan-6-one 2-(6-(2-(2-aminoethoxy)benzyl)-2-azaspiro[3.3]heptane-2-carbonyl)-7-oxa-2,5- diazaspiro[3.4]octan-6-one (12.0 mg, 0.03 mmol) from step c) was dissolved in MeOH (0.75 mL) and trimethylamine (13.0 ⁇ L, 0.09 mmol) was added.
- the reaction was stirred at room in the dark for approximately 4h (LC-MS monitoring of the reaction). Then diluted with H 2 O/ACN and freeze dried. The crude was purified by RP-HPLC H 2 O/ACN with 0.1% TFA 25 to 75% in 30 min to afford the target product (6.0 mg, 7.0 ⁇ mol, 76%).
- Example 32 is a regioisomeric mixture of 5- and 6-carboxytetramethylrhodamine derivatives that was obtained in one reaction. HPLC purification allowed to separate a fraction ofthe 5- carboxytetramethylrhodamine derivative (example 33) from the mixture. The respective 6- carboxytetramethylrhodamine derivative could not be obtained in pure form. The same considerations apply to examples 34 and 35 and 36 and 37, respectively.
- Example 38 was obtained as 5- and 6-carboxytetramethylrhodamine derivative regioisomeric mixture.
- Example 39 Ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)benzoate Step d tert-butyl 3-((3-(ethoxycarbonyl)phenoxy)methyl)azetidine-1-carboxylate (BB15) In analogy to the procedure described in Example 1 d), ethyl 3-hydroxy benzoate (CAS RN 7781-98-8) was reacted with tert-butyl 3-(bromomethyl)azetidine-1-carboxylate (CAS RN 253176-93-1) to afford the title compound (18.0 mg, 0.05 mmol, 18%).
- Example 42 tert-Butyl (2-(3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)benzamido)ethyl)carbamate
- Step k Ester hydrolysis.
- Ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3- b][1,4]oxazine-6-carbonyl)azetidin-3-yl)oxy)benzoate (Example 40, 12.5 mg, 0.03 mmol) was dissolved in THF/MeOH/H2O 3:1:1 (0.2 mL) and lithium hydroxide (LiOH, 2,15 mg, 0.09 mmol) was added. The reaction was stirred at room temperature until completion (ca. 2h). The reaction was quenched by diluting with ethyl acetate (1.0 mL), extracted with aq.
- benzyl bromide (CAS RN 100-39-0, 0.16 mL, 1.38 mmol) was added. The reaction was allowed to warm up to room temperature and was stirred for 16 h. The mixture was diluted with dichloromethane (10.0 mL), neutralized with acetic acid, extracted with aq. sat. NaHCO3 (10 mL) and washed with water (10 mL). The organic layer was dried over MgSO 4 , filtrated, and concentrated in vacuo. The crude was purified via silica gel flash chromatography using ethyl acetate in cyclohexane 0 to 80% as eluent, to afford the title compound (120 mg, 0.43 mmol, 77%).
- step a1 (4aR,8aS)-6-(3-((benzyloxy)methyl)azetidine-1-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one
- a1 tert-Butyl 3- ((benzyloxy)methyl)azetidine-1-carboxylate was reacted with 4aR,8aS)-3-oxooctahydro- 2H-pyrido[4,3-b][1,4]oxazin-6-ium (2S,3S)-3-carboxy-2,3-bis((4- methylbenzoyl)oxy)propanoate salt (CAS RN 2624363-49-9) to afford the title compound.
- Step a1 (4aR,8aS)-6-(6-(benzyloxy)-2-azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one
- a1 tert-Butyl 6-(benzyloxy)-2- azaspiro[3.3]heptane-2-carboxylate was reacted with 4aR,8aS)-3-oxooctahydro-2H- pyrido[4,3-b][1,4]oxazin-6-ium (2S,3S)-3-carboxy-2,3-bis((4- methylbenzoyl)oxy)propanoate salt (CAS RN 2624363-49-9) to afford the title compound.
- Step e Benzyl (2-(3-(hydroxymethyl)phenoxy)ethyl)carbamate
- ethyl 3-(2- (((benzyloxy)carbonyl)amino)ethoxy)benzoate was reacted to afford the title compound (115 mg, 0.38 mmol, 66%).
- Step f Benzyl (2-(3-(bromomethyl)phenoxy)ethyl)carbamate
- benzyl (2-(3- (hydroxymethyl)phenoxy)ethyl)carbamate was reacted to afford the title compound (503 mg, 1.38 mmol, 63%).
- Step g tert-Butyl 3-(((3-(2- (((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carboxylate
- Benzyl (2-(3- (bromomethyl)phenoxy)ethyl)carbamate was reacted with tert-butyl 3- (hydroxymethyl)azetidine-1-carboxylate (CAS RN 142253-56-3) to afford the title compound (85.0 mg, 0.18 mmol, 55%).
- Step e Benzyl (3-(2-(hydroxymethyl)phenoxy)propyl)carbamate
- Ethyl 2-(3- (((benzyloxy)carbonyl)amino)propoxy)benzoate was reacted to afford the title compound (2.35 g, 7.45 mmol, 98%).
- Step f Benzyl (3-(2-(bromomethyl)phenoxy)propyl)carbamate
- benzyl (3-(2- (hydroxymethyl)phenoxy)propyl)carbamate was reacted to afford the title compound (2.00 g, 5.29 mmol, 80%).
- Step e Benzyl (5-(2-(hydroxymethyl)phenoxy)pentyl)carbamate
- ethyl 2-((5- (((benzyloxy)carbonyl)amino)pentyl)oxy)benzoate was reacted to afford the title compound (737 mg, 2.15 mmol, 86%).
- Step f tert-Butyl 3-(((2-((5- (((benzyloxy)carbonyl)amino)pentyl)oxy)benzyl)oxy)methyl)azetidine-1-carboxylate
- benzyl (5-(2- (hydroxymethyl)phenoxy)pentyl)carbamate was reacted with tert-butyl 3- (hydroxymethyl)azetidine-1-carboxylate (CAS RN 142253-56-3) to afford the title compound 67.6 mg, 0.132 mmol, 53%) was obtained.
- Step d Benzyl (2-(2-bromophenoxy)ethyl)carbamate
- 2-bromophenol CAS 95-56-7
- 2-(((benzyloxy)carbonyl)amino)ethyl 4-methylbenzenesulfonate CAS RN 93407-96-6
- the title compound 985 mg, 2.81 mmol, 94%).
- Step h tert-Butyl 6-(2-((5-(((benzyloxy)carbonyl)amino)pentyl)oxy)benzylidene)-2- azaspiro[3.3]heptane-2-carboxylate
- Benzyl (5-(2- bromophenoxy)pentyl)carbamate was reacted with tert-butyl 6-((4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)methylene)-2-azaspiro[3.3]heptane-2-carboxylate to afford the title compound (100 mg, 0.19 mmol, 25%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides compounds having the general formula (I) or (II) or pharmaceutically acceptable salts thereof, wherein A, L, n, and R1 to R3 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
Description
F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland Case: P37509 FLUORESCENT PROBES FOR MAGL Field of the Invention The present invention relates to organic compounds useful as fluorescent probes for monoacylglycerol lipase (MAGL). Background of the Invention Fluorescent imaging probes have emerged as high resolution tools to investigate localization, e.g. expression levels and protein distribution in health and disease, structure, dynamics and function of proteins in living cells (L. A. Stoddart, L. E. Kilpatrick, S. J. Briddon, S. J. Hill, Neuropharmacology 2015, 98, 48-57). Such probes can e.g. be applied in flow cytometry fluorescence-activated cell sorting (FACS) experiments or cellular trafficking studies using confocal live cell imaging. Furthermore, fluorescent imaging probes allow for real-time monitoring of ligand-receptor interactions and protein visualization with high spatiotemporal precision (A. J. Vernall, S. J. Hill, B. Kellam, Br. J. Pharmacol.2014, 171, 1073–1084; C. Iliopoulos-Tsoutsouvas, R. N. Kulkarni, A. Makriyannis, S. P. Nikas, Expert Opin. Drug Discov.2018, 13, 933–947). In addition, such probes offer the potential for generating equilibrium and kinetic binding data in a high-throughput fashion, without handling radioactive material using e.g. time-resolved fluorescence resonance energy transfer (TR-FRET). Fluorescent imaging probes can also be useful to support the translation of preclinical pharmacological animal data to clinics and can be applied for dose selection in humans. They can e.g. be used as markers of target engagement via the generation of ex vivo quantitative receptor binding data in whole blood. Depending on the respective application, a fluorescent imaging probe needs to match specific criteria, including affinity, selectivity and specificity for the respective target, favorable photophysical properties, and applicability across distinct techniques and cell types. CNE/14.08.2023
Summary of the Invention In a first aspect, the present invention provides a compound of formula (I) or (II)
or a pharmaceutically acceptable salt thereof, wherein A, L, n, and R1 to R3 are as defined herein. In a further aspect, the present invention provides processes for manufacturing said compounds of formula (I) or (II). In a further aspect, the present invention provides a compound of formula (I) or (II) as described herein, when manufactured according to the processes described herein. In a further aspect, the present invention provides the use of a compound of formula (II) described herein for the preparation of a fluorescent probe of formula (I) described herein. In a further aspect, the present invention provides a method of studying monoacylglycerol lipase (MAGL) occupancy, comprising contacting MAGL with a compound of formula (I) described herein. In a further aspect, the present invention provides a method of diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal, comprising contacting MAGL with a compound of formula (I) described herein. In a further aspect, the present invention provides a method of generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data, comprising contacting MAGL with a compound of formula (I) described herein.
Detailed Description of the Invention Definitions Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein, unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed. The term "heteroaryl" refers to a mono- or multivalent, monocyclic, bicyclic or tricyclic, preferably bicyclic ring system having a total of 5 to 14 ring members, preferably, 5 to 12 ring members, and more preferably 5 to 10 ring members, wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms. Preferably, “heteroaryl” refers to a 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. Most preferably, “heteroaryl” refers to a 5-10 membered heteroaryl comprising 1 to 2 heteroatoms independently selected from O, S and N. Some non-limiting examples of heteroaryl include spiro[cyclopropane-1,3'- indoline] (e.g., spiro[cyclopropane-1,3'-indoline]-1'-yl), 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazin-2-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, indol-1-yl, 1H-indol-2-yl, 1H-indol-3-yl, 1H-indol-4-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1H-indol-7-yl, 1,2-benzoxazol-3-yl, 1,2-benzoxazol-4-yl, 1,2-benzoxazol-5-yl, 1,2-benzoxazol-6-yl, 1,2- benzoxazol-7-yl, 1H-indazol-3-yl, 1H-indazol-4-yl, 1H-indazol-5-yl, 1H-indazol-6-yl, 1H- indazol-7-yl, pyrazol-1-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, pyrazolo[1,5-a]pyridine, 2H-pyrazolo[4,3-b]pyridine, [1,2,4]triazolo[1,5-a]pyridine, 1H- pyrrolo[2,3-b]pyridine, imidazol-1-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, 1H-imidazol- 5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, thiazol-2- yl, thiazol-4-yl, thiazol-5-yl, pyridazin-3-yl, pyridazin-4-yl, 1,2,4-triazol-4-yl, 1,2,4- triazol-1-yl, 4H-1,2,4-triazol-3-yl, 4,5,6,7-tetrahydroindazol-2-yl, 6,7-dihydro-4H-
pyrano[4,3-c]pyrazol-2-yl, thiazolyl, benzofurazan-4-yl, tetrazolyl, isoxazolyl, pyrrolyl, and morpholinyl. The term "aryl" refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of 6 to 10 ring members (“C6-C10-aryl”), wherein at least one ring in the system is aromatic. Some non-limiting examples of aryl include phenyl and 9H-fluorenyl (e.g.9H-fluoren-9-yl). A particularly preferred, yet non-limiting example of aryl is phenyl. The term “alkyl” refers to a mono- or multivalent, e.g., a mono- or bivalent, linear or branched saturated hydrocarbon group of 1 to 12 carbon atoms. In some preferred embodiments, the alkyl group contains 1 to 6 carbon atoms, e.g., 1, 2, 3, 4, 5, or 6 carbon atoms (“C1-C6-alkyl”). In other embodiments, the alkyl group contains 1 to 3 carbon atoms, e.g., 1, 2 or 3 carbon atoms. Some non-limiting examples of alkyl include methyl, ethyl, propyl, 2-propyl (isopropyl), n-butyl, iso-butyl, sec-butyl, tert-butyl, and 2,2- dimethylpropyl. A particularly preferred, yet non-limiting example of alkyl is methyl. The term “alkoxy” refers to an alkyl group, as previously defined, attached to the parent molecular moiety via an oxygen atom. Unless otherwise specified, the alkoxy group contains 1 to 12 carbon atoms. In some preferred embodiments, the alkoxy group contains 1 to 6 carbon atoms (“C1-C6-alkoxy”). In other embodiments, the alkoxy group contains 1 to 4 carbon atoms. In still other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non-limiting examples of alkoxy groups include methoxy, ethoxy, n- propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy. A particularly preferred, yet non-limiting example of alkoxy is methoxy. The term “alkoxycarbonyl” refers to an alkoxy group, as previously defined, attached to the parent molecular moiety via a carbonyl group. In some preferred embodiments, the alkoxy moiety of the alkoxycarbonyl group contains 1 to 6 carbon atoms (“C1-C6- alkoxycarbonyl”). In other embodiments, the alkoxy group contains 1 to 4 carbon atoms. In still other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non- limiting examples of alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, n- propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl and tert- butoxycarbonyl. A particularly preferred, yet non-limiting example of alkoxy is tert- butoxycarbonyl.
The term "pharmaceutically acceptable salt" refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like. In addition, these salts may be prepared by addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like. Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N- ethylpiperidine, piperidine, polyimine resins and the like. Particular pharmaceutically acceptable salts of compounds of formula (I) are hydrochloride salts. The compounds of formula (I) can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereioisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. According to the Cahn-Ingold-Prelog Convention, the asymmetric carbon atom can be of the "R" or "S" configuration. The abbreviation “MAGL” refers to the enzyme monoacylglycerol lipase. The terms “MAGL” and “monoacylglycerol lipase” are used herein interchangeably. Compounds of the Invention In a first aspect, the present invention provides a compound of formula (I) or (II)
A A n (I) (II) or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from:
; wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I) or (II); R2 is selected from:
, , , p p , , and ; wherein: a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1 or 2;
is selected from hydrogen and methyl; W is selected from methyl, phenyl,
, , ,
, , ; wherein Ar is C6-C10-aryl or 5- to 14-membered heteroaryl;
is selected from O, S, Si(CH3)2, and CH2; and
is selected from OH, NH2, N(CH3)2, N(CD3)2, and azetidin-1-yl;
R3 is selected from hydrogen, C1-C6-alkoxycarbonyl and C1-C6-alkoxycarbonyl- NH-C1-C6-alkyl-NH-C(O)–;
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I) or (II), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I) or (II); and n is an integer selected from 1, 2, 3 and 4. In one embodiment, the present invention provides a compound of formula (I) or (II) as described herein or a pharmaceutically acceptable salt thereof, wherein: in Formula (I), R1 is selected from:
, , , and ; wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I); in Formula (II), R1 is selected from:
wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (II); R2 is selected from:
, , , p p , , and ; wherein: a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1 or 2; V is selected from hydrogen and methyl; ,
Ar is C6-C10-aryl or 5- to 14-membered heteroaryl; X is selected from O, S, Si(CH3)2, and CH2; and Y is selected from OH, NH2, N(CH3)2, N(CD3)2, and azetidin-1-yl;
R3 is selected from hydrogen, C1-C6-alkoxycarbonyl and C1-C6-alkoxycarbonyl- NH-C1-C6-alkyl-NH-C(O)–; A is:
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I) or (II), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I) or (II); and n is an integer selected from 1, 2, 3 and 4. In one aspect, the present invention provides a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein R1, R2, A, L, and n are as defined herein. In one aspect, the present invention provides a compound of formula (II)
or a pharmaceutically acceptable salt thereof, wherein R1, R3, A, and L are as defined herein. In one embodiment, the present invention provides a compound of formula (I) or (II) as described herein, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from:
wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I). In one embodiment, the present invention provides a compound of formula (I) or (II) as described herein, or a pharmaceutically acceptable salt thereof, wherein R1 is
; wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I). In one embodiment, the present invention provides a compound of formula (I) or (II) as described herein, or a pharmaceutically acceptable salt thereof, wherein R1 is
;
wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I). In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is:
(i) X is CH; and L is selected from –CH2– and –CH2O–; or
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I). In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is:
; (i) X is CH and L is –CH2–; or
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I). In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is:
X is CH; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I). In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is
wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I). In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is
and L is –CH2–; wherein X is CH;
a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I). In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R2 is selected from: ,
a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; and n is an integer selected from 1, 2, and 4. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R2 is selected from:
, , , and p ; wherein: a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; and n is an integer selected from 1, 2, and 4. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R2 is selected from:
, , , and p ; wherein: a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; and n is an integer selected from 1 and 4. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: 2
R is ; wherein: the wavy line indicates the point of attachment of R2 to the remainder of formula (I); and n is an integer selected from 1 and 4. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:
R2 is ; wherein: the wavy line indicates the point of attachment of R2 to the remainder of formula (I); V is methyl; W is methyl; and n is an integer selected from 1 and 4. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R2
; wherein: the wavy line indicates the point of attachment of R2 to the remainder of formula (I); X is selected from O and Si(CH3)2; Y is N(CH3)2; and n is an integer selected from 1 and 4. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R2
wherein:
the wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; and n is an integer selected from 1 and 4. In one embodiment, the present invention provides a compound of formula (II) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is:
(i) and L is selected from –OCH2–, –CH2OCH2–, and –O–; or
(ii) and L is –CH2O–; wherein X is CH; wherein a wavy line indicates the point of attachment to L; and an asterisk indicates the point of attachment to the carbonyl group of formula (II). In one embodiment, the present invention provides a compound of formula (I) as described herein, wherein: R1 is selected from:
; wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I); R2 is selected from:
, , , p , and ; wherein: a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; A is:
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points
of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment to L; and an asterisk indicates the point of attachment to the carbonyl group of formula (I); and n is an integer selected from 1, 2, and 4. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, wherein: R1 is selected from:
wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I); R2 is selected from:
a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and
Y is N(CH3)2; A is:
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I); and n is an integer selected from 1, 2, and 4. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, wherein:
wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I); R2 is selected from:
, , , and p ; wherein: a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; A is:
X is CH; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I); and n is an integer selected from 1 and 4. In one embodiment, the present invention provides a compound of formula (I) or (II) as described herein, wherein the compound of formula (I) or (II) is selected from:
benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)- 2-azaspiro[3.3]heptan-6-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)- 2-azaspiro[3.5]nonan-7-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-(((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)- 2-azaspiro[3.3]heptan-6-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (3-(3-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)propyl)carbamate; benzyl (6-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)hexyl)carbamate; benzyl (2-(2-(((1-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate; cyclohex-1-en-1-ylmethyl (2-(2-((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3- b][1,4]oxazine-6-carbonyl)-2-azaspiro[3.3]heptan-6- ylidene)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((7-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)- 7-azaspiro[3.5]nonan-2-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (5-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)pentyl)carbamate; benzyl (2-(2-((((1R,5S)-3-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)methoxy)methyl)phenoxy)ethyl)carbamate;
benzyl (R)-(2-(2-(((1-(3-(2-oxooxazolidin-4-yl)propanoyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((1-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate; 2-(6-(2-(2-((7-nitro-1l2,3l2-benzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)benzyl)-2- azaspiro[3.3]heptane-2-carbonyl)-7-oxa-2,5-diazaspiro[3.4]octan-6-one; (4aR,8aS)-6-(3-(((2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4- yl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; 2-(3-(((2-(2-((7-nitro-1H-3l2-benzo[c][1,2,5]oxadiazol-4- yl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carbonyl)-7-oxa-2,5- diazaspiro[3.4]octan-6-one; (4aR,8aS)-6-(3-(((2-(3-((7-nitrobenzo[c][1,2,5]oxadiazol-4- yl)amino)propoxy)benzyl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(3-(((2-((5-((7-nitro-1,3-dihydrobenzo[c][1,2,5]oxadiazol-4- yl)amino)pentyl)oxy)benzyl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(6-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)benzyl)-2- azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(6-(3-(2-((7-nitro-1,3-dihydrobenzo[c][1,2,5]oxadiazol-4- yl)amino)ethoxy)benzyl)-2-azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; 2-(7-(Dimethylamino)-3-(dimethyliminio)-5,5-dimethyl-3,5-dihydrodibenzo[b,e]silin-10- yl)-4-((5-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-yl)methyl)phenoxy)pentyl)carbamoyl)benzoate; 3,3-dimethyl-1-(6-oxo-6-((2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-yl)methyl)phenoxy)ethyl)amino)hexyl)-2-((E)-3-((Z)-1,3,3- trimethylindolin-2-ylidene)prop-1-en-1-yl)-3H-indol-1-ium 2,2,2-trifluoroacetate; 3-(5,5-difluoro-7,9-dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)- N-(2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan- 6-yl)methyl)phenoxy)ethyl)propanamide; 2,2,2-trifluoroacetic acid, 3,3-dimethyl-1-(6-oxo-6-((2-(2-(((1-((4aR,8aS)-3-oxooctahydro- 2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3-
yl)methoxy)methyl)phenoxy)ethyl)amino)hexyl)-2-((E)-3-((Z)-1,3,3-trimethylindolin- 2-ylidene)prop-1-en-1-yl)-3H-indol-1-ium salt; 3,3-dimethyl-1-(6-oxo-6-((2-(2-((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3- b][1,4]oxazine-6-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)ethyl)amino)hexyl)-2-((E)-3-((Z)-1,3,3-trimethylindolin-2- ylidene)prop-1-en-1-yl)-3H-indol-1-ium 2,2,2-trifluoroacetate; 3-(5,5-difluoro-7,9-dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)- N-(2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)propanamide; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((2-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamoyl)benzoate and 2-(6-(dimethylamino)-3- (dimethyliminio)-3H-xanthen-9-yl)-5-((2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H- pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((2-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((3-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)propyl)carbamoyl)benzoate and 2-(6-(dimethylamino)-3- (dimethyliminio)-3H-xanthen-9-yl)-5-((3-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H- pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)propyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((3-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)propyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((5-(2-((2-(6-oxo-7-oxa- 2,5-diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)pentyl)carbamoyl)benzoate compound and 2-(6-(dimethylamino)-3- (dimethyliminio)-3H-xanthen-9-yl)-5-((5-(2-((2-(6-oxo-7-oxa-2,5- diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)pentyl)carbamoyl)benzoate;
2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((5-(2-((2-(6-oxo-7-oxa- 2,5-diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)pentyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((5-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)pentyl)carbamoyl)benzoate and 2-(6-(dimethylamino)-3- (dimethyliminio)-3H-xanthen-9-yl)-5-((5-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H- pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)pentyl)carbamoyl)benzoate; ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin- 3-yl)methoxy)benzoate; ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin- 3-yl)oxy)benzoate; ethyl 2-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin- 3-yl)methoxy)benzoate; tert-Butyl (2-(3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)benzamido)ethyl)carbamate; tert-butyl (2-(2-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)benzamido)ethyl)carbamate; (4aR,8aS)-6-(3-((benzyloxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(6-(benzyloxy)-2-azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; and (4aR,8aS)-6-(3-(phenoxymethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one. In one embodiment, the present invention provides a compound of formula (I) as described herein, wherein the compound of formula (I) is selected from: benzyl (6-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)hexyl)carbamate; benzyl (2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)ethyl)carbamate; benzyl (5-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)pentyl)carbamate;
benzyl (R)-(2-(2-(((1-(3-(2-oxooxazolidin-4-yl)propanoyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((1-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate; 2-(6-(2-(2-((7-nitro-1l2,3l2-benzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)benzyl)-2- azaspiro[3.3]heptane-2-carbonyl)-7-oxa-2,5-diazaspiro[3.4]octan-6-one; (4aR,8aS)-6-(3-(((2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4- yl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; 2-(3-(((2-(2-((7-nitro-1H-3l2-benzo[c][1,2,5]oxadiazol-4- yl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carbonyl)-7-oxa-2,5- diazaspiro[3.4]octan-6-one; (4aR,8aS)-6-(3-(((2-(3-((7-nitrobenzo[c][1,2,5]oxadiazol-4- yl)amino)propoxy)benzyl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(3-(((2-((5-((7-nitro-1,3-dihydrobenzo[c][1,2,5]oxadiazol-4- yl)amino)pentyl)oxy)benzyl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(6-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)benzyl)-2- azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(6-(3-(2-((7-nitro-1,3-dihydrobenzo[c][1,2,5]oxadiazol-4- yl)amino)ethoxy)benzyl)-2-azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; 2-(7-(Dimethylamino)-3-(dimethyliminio)-5,5-dimethyl-3,5-dihydrodibenzo[b,e]silin-10- yl)-4-((5-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-yl)methyl)phenoxy)pentyl)carbamoyl)benzoate; 3,3-dimethyl-1-(6-oxo-6-((2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-yl)methyl)phenoxy)ethyl)amino)hexyl)-2-((E)-3-((Z)-1,3,3- trimethylindolin-2-ylidene)prop-1-en-1-yl)-3H-indol-1-ium 2,2,2-trifluoroacetate; 3-(5,5-difluoro-7,9-dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)- N-(2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan- 6-yl)methyl)phenoxy)ethyl)propanamide; 2,2,2-trifluoroacetic acid, 3,3-dimethyl-1-(6-oxo-6-((2-(2-(((1-((4aR,8aS)-3-oxooctahydro- 2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3-
yl)methoxy)methyl)phenoxy)ethyl)amino)hexyl)-2-((E)-3-((Z)-1,3,3-trimethylindolin- 2-ylidene)prop-1-en-1-yl)-3H-indol-1-ium salt; 3,3-dimethyl-1-(6-oxo-6-((2-(2-((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3- b][1,4]oxazine-6-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)ethyl)amino)hexyl)-2-((E)-3-((Z)-1,3,3-trimethylindolin-2- ylidene)prop-1-en-1-yl)-3H-indol-1-ium 2,2,2-trifluoroacetate; 3-(5,5-difluoro-7,9-dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)- N-(2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)propanamide; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((2-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamoyl)benzoate and 2-(6-(dimethylamino)-3- (dimethyliminio)-3H-xanthen-9-yl)-5-((2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H- pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((2-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((3-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)propyl)carbamoyl)benzoate and 2-(6-(dimethylamino)-3- (dimethyliminio)-3H-xanthen-9-yl)-5-((3-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H- pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)propyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((3-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)propyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((5-(2-((2-(6-oxo-7-oxa- 2,5-diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)pentyl)carbamoyl)benzoate compound and 2-(6-(dimethylamino)-3- (dimethyliminio)-3H-xanthen-9-yl)-5-((5-(2-((2-(6-oxo-7-oxa-2,5- diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)pentyl)carbamoyl)benzoate;
2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((5-(2-((2-(6-oxo-7-oxa- 2,5-diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)pentyl)carbamoyl)benzoate; and 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((5-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)pentyl)carbamoyl)benzoate and 2-(6-(dimethylamino)-3- (dimethyliminio)-3H-xanthen-9-yl)-5-((5-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H- pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)pentyl)carbamoyl)benzoate. In one embodiment, the present invention provides a compound of formula (II) as described herein, wherein the compound of formula (II) is selected from: benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)- 2-azaspiro[3.3]heptan-6-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)- 2-azaspiro[3.5]nonan-7-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-(((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)- 2-azaspiro[3.3]heptan-6-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (3-(3-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)propyl)carbamate; benzyl (2-(2-(((1-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate; cyclohex-1-en-1-ylmethyl (2-(2-((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3- b][1,4]oxazine-6-carbonyl)-2-azaspiro[3.3]heptan-6- ylidene)methyl)phenoxy)ethyl)carbamate;
benzyl (2-(3-((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((7-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)- 7-azaspiro[3.5]nonan-2-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-((((1R,5S)-3-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)methoxy)methyl)phenoxy)ethyl)carbamate; ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin- 3-yl)methoxy)benzoate; ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin- 3-yl)oxy)benzoate; ethyl 2-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin- 3-yl)methoxy)benzoate; tert-Butyl (2-(3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)benzamido)ethyl)carbamate; tert-butyl (2-(2-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)benzamido)ethyl)carbamate; (4aR,8aS)-6-(3-((benzyloxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(6-(benzyloxy)-2-azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; and (4aR,8aS)-6-(3-(phenoxymethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one. In a particular embodiment, the present invention provides pharmaceutically acceptable salts of the compounds according to formula (I) as described herein. In a further particular embodiment, the present invention provides compounds according to formula (I) as described herein as free bases. Processes of Manufacturing The preparation of compounds of formula (I) or (II) of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following general schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those persons skilled in the art. The
substituents and indices used in the following description of the processes have the significance given herein, unless indicated to the contrary. If one of the starting materials, intermediates or compounds of formula (I) or (II) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protective groups (as described e.g., in “Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wutts, 5th Ed., 2014, John Wiley & Sons, N.Y.) can be introduced before the critical step applying methods well known in the art. Such protective groups can be removed at a later stage of the synthesis using standard methods described in the literature. If starting materials or intermediates contain stereogenic centers, compounds of formula (I) or (II) can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art e.g., chiral HPLC, chiral SFC or chiral crystallization. Racemic compounds can e.g., be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes by specific chromatographic methods using either a chiral adsorbent or a chiral eluent. It is equally possible to separate starting materials and intermediates containing stereogenic centers to afford diastereomerically/enantiomerically enriched starting materials and intermediates. Using such diastereomerically/enantiomerically enriched starting materials and intermediates in the synthesis of compounds of formula (I) or (II) will typically lead to the respective diastereomerically/enantiomerically enriched compounds of formula (I) or (II). A person skilled in the art will acknowledge that in the synthesis of compounds of formula (I) or (II) - insofar not desired otherwise - an “orthogonal protection group strategy” will be applied, allowing the cleavage of several protective groups one at a time each without affecting other protective groups in the molecule. The principle of orthogonal protection is well known in the art and has also been described in literature (e.g. Barany and R. B. Merrifield, J. Am. Chem. Soc.1977, 99, 7363; H. Waldmann et al., Angew. Chem. Int. Ed. Engl.1996, 35, 2056). A person skilled in the art will acknowledge that the sequence of reactions may be varied depending on reactivity and nature of the intermediates.
In more detail, the compounds of formula (I) or (II) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Also, for reaction conditions described in literature affecting the described reactions see for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY.1999). It was found convenient to carry out the reactions in the presence or absence of a solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. The described reactions can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. It is convenient to carry out the described reactions in a temperature range between -78 °C to reflux. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 hours to several days will usually suffice to yield the described intermediates and compounds. The reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity, the sequence of reaction steps can be freely altered. If starting materials or intermediates are not commercially available or their synthesis not described in literature, they can be prepared in analogy to existing procedures for close analogues or as outlined in the experimental section. The following abbreviations are used in the present text: AcOH = acetic acid, ACN = acetonitrile , Boc = tert-butyloxycarbonyl, CAS RN = chemical abstracts registration number, Cbz = benzyloxycarbonyl, Cs2CO3 = cesium carbonate, CO = carbon monoxide, DMAP = 4-dimethylaminopyridine, DMF = N,N-dimethylformamide, DMP = Dess-Martin periodinane, DIBAL-H = Diisobutylaluminium hydride, DIPEA = N,N-diisopropylethylamine, dppf = 1,1 bis(diphenyl phosphino)ferrocene, EDC.HCl = N- (3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, ESI = electrospray ionization, EtOAc = ethyl acetate, EtOH = ethanol, h = hour(s), FA = formic acid, H2O = water, H2SO4 = sulfuric acid, Hal = halogen, HATU = 1-[bis(dimethylamino)methylene]- 1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate, HBTU = O- benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate, HCl = hydrogen chloride, HOBt = 1-hydroxy-1H-benzotriazole; HPLC = high performance liquid
chromatography, , , K2CO3 = potassium carbonate, KHCO3 = potassium bicarbonate, KI = potassium iodide, KOH = potassium hydroxide, K3PO4 = potassium phosphate tribasic, KOtBu = potassium tert-butoxide, LiAlH4 or LAH = lithium aluminium hydride, LiHMDS = lithium bis(trimethylsilyl)amide, LiOH = lithium hydroxide, LiTMP = lithium tetramehtyl-piperidine MgSO4 = magnesium sulfate, min = minute(s), mL = milliliter, MPLC = medium pressure liquid chromatography, MS = mass spectrum, Ms = mesyl, NaH = sodium hydride, NaHCO3 = sodium hydrogen carbonate, , NaOH = sodium hydroxide, Na2CO3 = sodium carbonate, Na2SO4 = sodium sulfate, Na2S2O3 = sodium thiosulfate, NBS = N-bromosuccinimide, nBuLi = n-butyllithium, NEt3 = triethylamine (TEA), NH4Cl = ammonium chloride, , NMP = N-methyl-2-pyrrolidone, OAc = Acetoxy, T3P = propylphosphonic anhydride, , , PG = protective group, Pd-C = palladium on activated carbon, Pd(dppf)Cl2 = 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride, Pd2(dba)3 = tris(dibenzylideneacetone)dipalladium(0), Pd(OAc)2 = palladium(II) acetate, Pd(OH)2 = palladium hydroxide, Pd(PPh3)4 = tetrakis(triphenylphosphine)palladium(0), PTSA = p-toluenesulfonic acid, Ts, tosyl, R = any group, r.t. = room temperature, SFC = Supercritical Fluid Chromatography, TBAI = tetra butyl ammonium iodine, TEA = triethylamine, TFA = trifluroacetic acid, THF = tetrahydrofuran, TMEDA = N,N,N',N'- tetramethylethylenediamine, ,. Compounds of formula I wherein A, L, n, R1, and R2 are as described herein can be synthesized in analogy to literature procedures and/or as depicted for example in Scheme 1.
Scheme 1 Accordingly, amines derivatives 1 carry a suitable nitrogen protecting group “PG” at the end of the alkane chain, such as benzyloxycarbonyl (Cbz) carbamate, and an orthogonal nitrogen protecting group “PG1” at the cyclic amine, such as a tert-butyloxycarbonyl (Boc)
carbamate. Removal of the protective group PG1 intermediates 1, applying methods known in the art (e.g., a Boc group using TFA in DCM at temperatures between 0 °C and room temperature, a Cbz group using hydrogen in the presence of a suitable catalyst such as Pd or Pd(OH)2 on charcoal in a suitable solvent such as MeOH, EtOH, EtOAc or mixtures thereof and as described for example in “Protective Groups in Organic Chemistry” by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.), followed by reaction of the obtained free amine with compounds of the type 2a (R1 moieties that contain an N at the point of attachment to the remainder of formula I) in the presence of a urea forming reagent such as bis(trichloromethyl) carbonate using a suitable base and solvent such as, e.g. sodium bicarbonate in DCM, to furnish compounds 3, including compunds of the formula Ia (step a1). Further urea forming reagents include but are not limited to phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate or 1,1’-carbonyldiimidazole. Reactions of this type and the use of these reagents are widely described in literature (e.g. G. Sartori et al., Green Chemistry 2000, 2, 140). A person skilled in the art will acknowledge that the order of the addition of the reagents can be important in this type of reactions due to the reactivity and stability of the intermediary formed carbamoyl chlorides, as well as for avoiding formation of undesired symmetrical urea by-products. Alternatively, R1 moieties that contain a C at the point of attachment to the remainder of formula I are introduced as carboxyl acids that are coupled with intermediate amines obtained from following PG1 removal on 1, to form the respective amides, including compounds of the formula Ia (step a2). Amide couplings of this type can be accomplished by using one of the well-known coupling reagents such as DCC, HATU, EDCI, HOBt, TBTU, T3P, etc. and a base like Huenig’s base, triethylamine or DMAP in a suitable solvent like N,N-dimethylformamide, DMA, DCM or 1-4-dioxane, preferably between 0 °C and room temperature. Removal of the protective group in intermediates 3, applying methods known in the art (e.g., a Boc group using TFA in DCM at temperatures between 0 °C and room temperature, a Cbz group using hydrogen in the presence of a suitable catalyst such as Pd or Pd(OH)2 on charcoal in a suitable solvent such as MeOH, EtOH, EtOAc or mixtures thereof and as described for example in “Protective Groups in Organic Chemistry” by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.), furnishes intermediates 4 (step b). Reaction of amines 4 with a fluorescent label containing a carboxylic acid moiety gives compounds of formula Ib (R2 = fluorescent label) (step c). Amide couplings of this type can be accomplished by using one of the well-known coupling reagents such as, DCC, HATU, EDCI, HOBt, TBTU, T3P, etc. and a base like Huenig’s base, triethyl amine or DMAP in a
suitable solvent solvent like N,N-dimethylformamide, DMA, DCM or dioxane, preferably between 0 °C and room temperature. Alternatively, a fluorescent label containing an N- hydroxisuccinimide (NHS) activated ester can be reacted with 4 to afford compounds of the formula Ib in the presence of a suitable base, such as N,N-diisopropylethylamine (DIPEA), 2,6-lutidine, etc. in a suitable solvent such as DCM, THF, ACN, DMF, or dioxane, preferably between 0 °C and room temperature. To form final molecules Ib carrying a nitrobenzofurazan dye, amines 4 can be reacted in a nucleophic aromatic substitution with 4-chloro-7-nitrobenz-2-oxa-1,3-diazole (CAS RN 10199-89-0) or 4-fluoro-7-nitrobenz-2- oxa-1,3-diazole (CAS RN 29270-56-2), e.g. in the presence of a base such as triethylamine in a solvent as MeOH, preferably between 0 °C and room temperature (step c). Optionally, amine derivatives 1 in which “PG” is a fluorescent label can be converted directly to compounds of formula Ib according to step a. Protected amines 1 and their amine 2a or carboxylic acid 2b counterparts are either commercially available or can be prepared according to literature methods or as depicted below. Intermediates of type 1, such as intermediates 1a and 1b, can be prepared by a variety of conditions, which may be exemplified by the general synthetic procedure outlined in Scheme 2.
Scheme 2 Intermediates 5, 6 and 11 are either commercially available or can be prepared according to literature methods. The functional hydroxyl group in 5 and 11 can be utilized to attach alkane
chain derivatives of the type 6, where “LG” is a suitable leaving group such as, but not limited to, methanesulfonic ester (OMs), p-toluensulfonic ester (OTs), bromine, iodide, via nucleophilic substitution (SN) reactions in the presence of a suitable base (e.g. Cs2CO3, K2CO3), in a suitable solvent (e.g. DMF) preferably at temperatures between room temperature and 80 °C, to yield compounds 7 and 12, respectively (step d). Intermediates of the type 7 and 12 can also be obtained by other etherification reactions according to literature methods, or e.g. under Mitsunobu conditions with PPh3 and diethyl azodicarboxylate. Benzoic esters of type 7 can be transformed to their corresponding benzylic alcohols 8 by treatment with a suitable reducing agent, such as LiAlH4, LiBH4, diisobutylaluminium hydride (DIBAL-H), in a suitable solvent such as toluene, preferably at temperatures between -78° and 0° C (step e). Benzyl alcohols 8 can be converted into their benzyl bromide analogues 9 by reactions described in literature, such as Appel reaction with CBr4 and PPh3 or using PBr3, in a suitable solvent such as DCM, preferably at temperatures between 0 and 25 °C (step f). Molecules of the type 1a can be obtained by reacting benzyl bromides 9 with alcohols 10 in nucleophilic substitution reaction in presence of a suitable base, such as KOtBu, in a suitable solvent, such as THF, preferably at temperature between room temperature and 80 °C (step g). A person skilled in the art will acknowledge that other etherification methods describe in literature, as well as the use of analogues of bromine 9 that bear other suitable leaving groups instead of the bromine (e.g. I, OMs, OTs) can be used to produce 1a. Boronic acids, esters and their derivatives are known as versatile building blocks for transition metal mediated cross-coupling reactions. Intermediates of the type 1b can be readily accessed via cross-coupling reactions with suitable building blocks, such as vinyl boronic esters 13, in the presence of a suitable base such as K2CO3, a suitable water- containing solvent mixture such as water/dioxane, with a transition metal catalyst such as, but not limited to, Pd(dppf)Cl2, preferably at temperatures between 25 and 100 °C (step h). Alternatively, hydrolysis of vinyl boronates 13 by methods known to those skilled in the art, such as treatment with ammonium acetate buffered water/acetone mixtures and sodium periodate, can be conducted as an individual step, and subsequent (step h) can be conducted in absence of water. Vinyl boronic esters 13 are either commercially available or can be prepared according to literature methods or as depicted below. Vinyl boronates 13 (e.g. vinyl boronic acid pinacol ester) can be readily obtained as described in the literature (Kovalenko et al. , The Boron- Wittig Olefination of Aldehydes and Ketones with Bis[(pinacolato)boryl]methane: an
Extended Reaction Scope. Eur J. Org. Chem., 2019: 5264-5635), for instance by treatment of ketones 14 with bis((pinacolato)boryl)methane (CAS RN 78782-17-9), in presence of a suitable base, such as Lithium tetramethyl piperindine (LiTMP). The general synthetic method is depicted in Scheme 3 (step i).
Scheme 3 Compounds of formula II wherein A, L, R1, and R3 are as described herein can be synthesized in analogy to literature procedures and/or as depicted for example in Scheme 4.
Scheme 4 Amines of the type 15, bearing a protecting group “PG1” such as those described for intermediates 1, and a leaving group “LG” as those described for intermediate 6 are either commercially available on can be readily accessed in one step from alcohol derivatives 10 by methods widely described in literature (e.g. by reaction with p-toluensulfonic acid chloride in presence of DMAP and TEA, or Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY.1999, step j). Phenol ester derivatives 16 can be reacted via nucleophilic substitution with intermediates 15 to afford ether intermediates 17, in analogy to the methods described for the transformation of 5 to 7 in scheme 2 (step d).
Compounds of the type IIa can be obtained from 17 in analogy to the transformation of 1 to 3 in scheme 1 (step a). Compounds with the formula IIb can be obtained from reaction of IIa with amines 18 under amide coupling conditions, eg. by using one of the well-known coupling reagents such as, DCC, HATU, EDCI, HOBt, TBTU, T3P, etc. and a base like Huenig’s base, triethyl amine or DMAP in a suitable solvent solvent like N,N-dimethylformamide, DMA, DCM or dioxane, preferably at room temperature (step k). Treating benzyl bromide 19 with alcohols of the type 10 (see above) under nucleophilic substitution conditions, in the presence of a suitable base, such as sodium hydride (NaH) and a suitable solvent such as DMF/DCM mixture, preferably at temperatures between 0 and 25 °C affords ether intermediates 20 (step l). Compounds with the formula IIc, where R3 = H to the remainder of formula II, are readily accessed from 20, in analogy to that described for the transformation of 1 to 3 in scheme 1 (step a). In one aspect, the present invention provides a process of manufacturing the compounds of formula (I) as described herein, comprising reacting an amine 4,
wherein A, L, R1, and n are as defined herein, with: (a) a fluorescent label containing a carboxylic acid moiety in the presence of a coupling reagent and a base; or (b) a fluorescent label containing an N-hydroxisuccinimide (NHS) activated ester in the presence of a base; or (c) 4-chloro-7-nitrobenz-2-oxa-1,3-diazole or 4-fluoro-7-nitrobenz-2-oxa-1,3- diazole in in the presence of a base; to afford said compound of formula (I). In one embodiment, said fluorescent label containing a carboxylic acid moiety in reaction (a) is selected from:
, , p , and p ; wherein: X, Y, V, W, and p are as defined herein. In one embodiment, said coupling reagent in reaction (a) is selected from DCC, HATU, EDCI, HOBt, TBTU, and T3P. In one embodiment, said base in reaction (a) is selected from Huenig’s base, triethyl amine, and DMAP. In one embodiment, said reaction (a) is conducted in a suitable solvent solvent, preferably in a solvent selected from N,N-dimethylformamide, DMA, DCM, and dioxane. In one embodiment, said fluorescent label containing an N-hydroxisuccinimide (NHS) activated ester in reaction (b) is selected from:
, , p , and p ; wherein: X, Y, V, W, and p are as defined herein. In one embodiment, said base in reaction (b) is selected from N,N-diisopropylethylamine (DIPEA) and 2,6-lutidine. In one embodiment, said reaction (b) is conducted in a suitable solvent solvent, preferably in a solvent selected from DCM, THF, ACN, DMF, and dioxane. In one embodiment, said base in reaction (c) is triethylamine.
In one embodiment, said reaction (c) is conducted in a suitable solvent solvent, preferably in methanol. In one aspect, the present invention provides a compound of formula (I) or (II) as described herein, when manufactured according to any one of the processes described herein. MAGL Inhibitory Activity Compounds were profiled for MAGL inhibitory activity by determining the enzymatic activity by following the hydrolysis of the natural substrate 2-arachidonoylglycerol (2-AG) resulting in arachidonic acid, which can be followed by mass spectrometry. This assay is hereinafter abbreviated “2-AG assay”. The 2-AG assay was carried out in 384 well assay plates (PP, Greiner Cat# 784201) in a total volume of 20 µL. Compound dilutions were made in 100% DMSO (VWR Chemicals 23500.297) in a polypropylene plate in 3-fold dilution steps to give a final concentration range in the assay from 12.5 µM to 0.8 pM.0.25µL compound dilutions (100% DMSO) were added to 9 µL MAGL in assay buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka, 03690-100 mL), 0.01% (v/v) Tween. After shaking, the plate was incubated for 15 min at RT. To start the reaction, 10 µL 2-arachidonoylglycerol in assay buffer was added. The final concentrations in the assay was 50 pM MAGL and 8 µM 2- arachidonoylglyerol. After shaking and 30 min incubation at RT, the reaction was quenched by the addition of 40µL of ACN containing 4µM of d8-arachidonic acid. The amount of arachidonic acid was traced by an online SPE system (Agilent Rapidfire) coupled to a triple quadrupole mass spectrometer (Agilent 6460). A C18 SPE cartridge (G9205A) was used in an ACN/water liquid setup. The mass spectrometer was operated in negative electrospray mode following the mass transitions 303.1
259.1 for arachidonic acid and 311.1
267.0 for d8-arachidonic acid. The activity of the compounds was calculated based on the ratio of intensities [arachidonic acid / d8-arachidonic acid].
Table 1
The compounds of formula (I) are fluorescent imaging probes with high affinity for MAGL. They may thus be used as high resolution tools to investigate localization, e.g. expression levels and protein distribution in health and disease, structure, dynamics and function of MAGL in living cells. They may also be applied e.g. in flow cytometry
fluorescence-activated cell sorting (FACS) experiments or cellular trafficking studies using confocal live cell imaging. In one aspect, the present invention provides a compound of formula (I) described herein, for use in monoacylglycerol lipase (MAGL) occupancy studies. In a further aspect, the present invention provides a compound of formula (I) described herein, for use in diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal. In a further aspect, the present invention provides a compound of formula (I) described herein, for use in generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data. In a further aspect, the present invention provides using a compound of formula (I) described herein in monoacylglycerol lipase (MAGL) occupancy studies. In a further aspect, the present invention provides using a compound of formula (I) described herein in diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal. In a further aspect, the present invention provides using a compound of formula (I) described herein for generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data. In a further aspect, the present invention provides a method of studying monoacylglycerol lipase (MAGL) occupancy, comprising contacting MAGL with a compound of formula (I) described herein. In a further aspect, the present invention provides a method of diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal, comprising contacting MAGL with a compound of formula (I) described herein. In a further aspect, the present invention provides a method of generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data, comprising contacting MAGL with a compound of formula (I) described herein. The compounds of formula (II) are useful synthetic intermediates for the preparation of the fluorescent probes of formula (I). Thus, in one aspect, the present invention provides the use of a compound of formula (II) described herein for the preparation of a fluorescent probe of formula (I) described herein.
Examples The invention will be more fully understood by reference to the following examples. The claims should not, however, be construed as limited to the scope of the examples. In case the preparative examples are obtained as a mixture of enantiomers, the pure enantiomers can be separated by methods described herein or by methods known to the man skilled in the art, such as e.g., chiral chromatography (e.g., chiral SFC) or crystallization. All reaction examples and intermediates were prepared under an argon atmosphere if not specified otherwise. Example 1 Benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate
Step d Ethyl 2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzoate
Ethyl salicylate (CAS RN 118-61-6, 2.26 g, 13.6 mmol) was dissolved in DMF (8 mL), Cs2CO3 (4.43g, 13.6 mmol) was added, and the mixture was stirred at room temperature for five minutes. Next, 2-(((benzyloxy)carbonyl)amino)ethyl 4-methylbenzenesulfonate (CAS RN 93407-96-6, 2.80 g, 8.00 mmol) was added, and mixture was stirred at 55 °C for 18 h. The reaction was quenched by diluting with DCM (60 mL), extracted with aq. sn. 10% NaOH (2 x 40 mL) and washed with brine (50 mL). The organic layer was dried over MgSO4, filtrated and concentrated under reduced pressure. The crude was purified by silica gel flash chromatography (0 to 50% AcOEt in cyclohexane) to afford the title compound (2.54 g, 7.40 mmol, 92%). 1H NMR (300 MHz, CDCl3) δ 7.82 (dd, J = 7.8, 1.8 Hz, 1H), 7.45 (ddd, J = 8.2, 7.4, 1.8 Hz, 1H), 7.41 – 7.24 (m, 5H), 7.07 – 6.90 (m, 2H), 5.98 (s, 1H,
NHCbz), 5.12 (s, 2H, OCH2), 4.35 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.14 (t, J = 5.0 Hz, 2H, OCH2), 3.64 (m, 2H, CH2NHCbz), 1.36 (t, J = 7.1 Hz, 3H, OCH2CH3).13C NMR (75 MHz, CDCl3) δ 166.2, 158.44, 156.73 (C=O CO2Et, C=O Cbz, CAr-O) 136.8, 133.7, 131.9, 128.6, 128.11, 128.09, 121.1, 120.9, 114.3, 68.8 (OCH2), 66.8 (OCH2), 61.1 (OCH2), 40.6 (CH2NHCbz), 14.4 (CH3). LC-HRMS (ESI) calc. for C19H21NO5Na [M+Na]+: 366.1312; found: 366.1301. Step e Benzyl (2-(2-(hydroxymethyl)phenoxy)ethyl)carbamate
Ester ethyl 2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzoate (1.15 g, 3.35 mmol) was dissolved in toluene (11.2 mL) under N2 atmosphere at 0 °C, and a 1M DIBAL in DCM solution (15.1 mL, 15.1 mmol) was added dropwise. The reaction mixture was stirred at 0 °C until completion (1.5 h, TLC monitoring). The reaction was quenched by diluting with DCM (20 mL) and dropwise addition of AcOH (0.86 mL, 15.1 mmol). The mixture was then extracted with 10% aq. sn. NaOH (2 x 40 mL) and washed with brine (40 mL). The organic layer was dried over MgSO4, filtrated and concentrated under reduced pressure. The concentrate was purified by silica gel flash chromatography (0 to 65% AcOEt in cyclohexanes) to afford the title compound (817 mg, 2.71 mmol, 81%).1H NMR (300 MHz, CDCl3) δ 7.39 – 7.20 (m, 4H), 6.95 (td, J = 7.5, 1.1 Hz, 1H), 6.85 (d, J = 8.1 Hz, 1H), 5.12 (s, 2H, OCH2), 4.66 (s, 2H, OCH2), 4.10 (t, J = 5.0 Hz, 2H, OCH2), 3.63 (t, J = 5.0 Hz, 2H, CH2NHCbz).13C NMR (75 MHz, CDCl3) δ 156.9, 156.7 (C=O Cbz, CAr-O), 136.5, 129.5, 129.4, 129.3, 128.7, 128.3, 121.3, 111.6, 67.6 (OCH2), 67.1 (OCH2), 62.1 (OCH2), 40.8 (CH2-NHCbz). LC-HRMS (ESI) calc. for C17H20NO4 [M+H]+: 302.1386; found: 302.1365. Step f Benzyl (2-(2-(bromomethyl)phenoxy)ethyl)carbamate
Alcohol benzyl (2-(2-(hydroxymethyl)phenoxy)ethyl)carbamate (795 mg, 2.64 mmol) was dissolved in DCM (20.3mL) and cooled to 0 °C. Next, CBr4 (1.00 g, 3.04 mmol) was added followed by PPh3 (796 mg, 3.04 mmol, 1.5 M solution in DCM). The reaction mixture was stirred at r.t. until completion (10 min, TLC monitoring). The reaction was quenched by diluting with DCM (30 mL), extracted with aq. sat. NaHCO3 (2 x 30 mL) and washed with brine (20 mL). The organic layer was dried over MgSO4, filtrated and concentrated under reduced pressure. The concentrate was purified by silica gel flash chromatography (0 to 40%
AcOEt in cyclohexanes) to afford the title compound (694 mg, 1.90 mmol, 72%).1H NMR (300 MHz, CDCl3) δ 7.38 – 7.28 (m, 7H), 7.04 – 6.81 (m, 2H), 5.12 (s, 2H, OCH2 Cbz), 4.59 (d, J = 27.9 Hz, 2H, CH2-Br), 4.14 (t, J = 4.9 Hz, 2H, OCH2CH2-NHCbz), 3.68 (q, J = 5.3 Hz, 2H, OCH2CH2-NHCbz).13C NMR (75 MHz, CDCl3) δ 156.7, 136.7, 131.0, 130.6, 128.7, 128.1, 121.2, 111.8, 67.5 (-OCH2-), 66.9 (-OCH2-), 40.7 (-OCH2CH2-NHCbz), 29.7 (CH2-Br). LC-MS (ESI): 386.0 [M+Na]+. Step g tert-Butyl 3-(((2-(2-
tert-Butyl 3-(hydroxymethyl)azetidine-1-carboxylate (CAS RN 142253-56-3, 196 mg, 1.05 mmol) was dissolved in anhydrous THF (7 mL) at 0 °C, KOtBu (118 mg, 1.05 mmol) was added, and the mixture was stirred for 5 min. Next, bromine derivative benzyl (2-(2- (bromomethyl)phenoxy)ethyl)carbamate (254.9 mg, 0.70 mmol) was dissolved in anhydrous THF (1.5 mL) and added dropwise to the reaction mixture. The mixture was then allowed to warm up to r.t. and stirred for 4 h until completion (TLC monitoring). The reaction was quenched by diluting with DCM (10 mL) and dropwise addition of AcOH (0.1 mL, 1.05 mmol). The mixture was extracted with aq. sat. NaHCO3 (2 x 20 mL) and washed with brine (20 mL). The organic layer was dried over MgSO4, filtrated and concentrated under reduced pressure. The concentrate was purified by silica gel flash chromatography (0 to 40% AcOEt in cyclohexanes) to afford the title compound (186 mg, 0.40 mmol, 57%). 1H NMR (300 MHz, CDCl3) δ 7.39 – 7.23 (m, 7H), 6.96 (td, J = 7.4, 1.0 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 5.50 (s, 1H, NHCbz), 5.10 (s, 2H, OCH2), 4.54 (s, 2H, OCH2), 4.14 – 4.03 (m, 2H, OCH2), 3.86 (t, J = 8.4 Hz, 2H, OCH2), 3.67 – 3.51 (m, 6H, CH2NHCbz, 2 x N-CH2 azetidine), 2.78 – 2.63 (m, 1H, CH azetidine), 1.43 (s, 9H, 3 x CH3 Boc). 13C NMR (75 MHz, CDCl3) δ 156.5, 136.5, 129.9, 129.4, 128.7, 128.44, 128.38, 126.7, 121.2, 112.1, 79.4 (C(CH3) Boc), 72.7 (CH azetidine), 68.8 (OCH2), 67.6 (OCH2), 67.0 (OCH2), 40.8 (CH2-NHCbz), 28.5 (CH3 Boc). LC-HRMS (ESI) calc. for C26H35N2O6 [M+H]+: 471.2490; found: 471.2475. Step a1 Benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate 1. Boc deprotection N-Boc protected derivative tert-Butyl 3-(((2-(2- (((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carboxylate (BB1, 93.0 mg, 0.20 mmol) was dissolved in DCM (1.3 mL) at 0 °C and TFA (152 µL, 2.0 mmol)
was added. The reaction mixture was stirred at that temperature until Boc deprotection was complete (1 h, LC-MS monitoring). The reaction was diluted with toluene (3.00 mL), and coevaporated with toluene (3.00 mL) under reduced pressure twice. The 2,2,2- trifluoroacetate salt of the free amine 3-(((2-(2- (((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)azetidine was used in the next step (2) without further purification. 2. Urea coupling (4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazin-6-ium (2S,3S)- 3-carboxy-2,3-bis((4-methylbenzoyl)oxy)propanoate salt (CAS RN 2624363-49-9, 119 mg, 0.16 mmol) was dissolved in anhydrous acetonitrile (0.7 mL) and1,1′-Carbonyl-di-(1,2,4- triazole) (CAS RN 41864-22-6, 26.3 mg, 0.16 mmol), followed by triethylamine (0.16 mL, 1.12 mmol) were added. The reaction mixture was stirred at room temperature for 2 h. Then, the amine nucleophile from step 1 2,2,2-trifluoroacetate salt of 3-(((2-(2- (((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)azetidine was dissolved in ACN (0.5 mL) and added dropwise to the reaction mixture. The reaction mixture was heated to 50 °C and stirred at that temperature for 2.5 h. The reaction was quenched by diluting with DCM (5.00 mL), extracted with aq. sat. NaHCO3 (2.00 mL) and washed with brine (2.00 mL). The organic layer was dried over MgSO4, filtrated and concentrated under reduced pressure. The concentrate was purified by HPLC (25 to 75% ACN in H2O with 0.1% TFA) to afford the title compound (70.0 mg, 0.13 mmol, 79%). 1H NMR (300 MHz, MeOD) δ 7.37 – 7.16 (m, 7H, H-Ar), 6.96 – 6.84 (m, 2H, H-Ar), 5.05 (s, 2H, O-CH2-), 4.51 (s, 2H, O- CH2-), 4.25 – 4.06 (m, 2H), 4.06 – 3.88 (m, 4H), 3.82 – 3.62 (m, 3H), 3.58 – 3.45 (m, 4H), 3.32 – 3.20 (m, 3H), 2.99 – 2.83 (m, 2H), 2.80 – 2.66 (m, 1H, -CH- azetidine), 1.90 – 1.64 (m, 2H. –CH2- HHPO).13C NMR (75 MHz, MeOD) δ 171.2, 163.7 (2 x C=O urea, amide), 158.9, 158.0 (C=O Cbz, Cipso phenol), 138.3, 130.8, 130.3, 129.5, 129.0, 128.8, 127.8, 121.8, 112.9 (C-Ar), 73.0, 70.4, 69.18, 68.21, 68.1, 67.5, 55.2, 55.1, 50.4, 47.1, 41.5, 40.5, 30.4, 30.2. LC-HRMS (ESI) calc. for C29H37N4O7+ [M+H]+: 553.2657; found: 553.2665. If not indicated otherwise the following examples were synthesized in analogy to the synthesis described for Example 1 using suitable building blocks.
Example 15 Benzyl (2-(2-(((7-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-7-azaspiro[3.5]nonan-2-yl)oxy)methyl)phenoxy)ethyl)carbamate
Step g tert-Butyl 2-((2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)-7- azaspiro[3.5]nonane-7-carboxylate (BB 13)
In analogy to the procedure described in Example 1 g), benzyl (2-(2- (bromomethyl)phenoxy)ethyl)carbamate (see Example 1) was reacted with tert-butyl 6- hydroxy-2-azaspiro[3.3]heptane-2-carboxylate (CAS RN 240401-28-9), to afford the title compound (59.6 mg, 0.114 mmol, 76%).1H NMR (300 MHz, CDCl3) δ 7.38 – 7.26 (m, 7H), 6.95 (td, J = 7.5, 1.0 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 5.57 (s, 1H, NHCbz), 5.10 (s, 2H, OCH2), 4.41 (s, 2H, OCH2), 4.16 – 3.95 (m, 3H), 3.61 (q, J = 5.3 Hz, 2H), 3.23 (dt, J = 20.9, 5.7 Hz, 4H), 2.12 (t, J = 10.0 Hz, 2H), 1.80 – 1.57 (m, 3H), 1.45 (m, 12H). 13C NMR (75 MHz, CDCl3) δ 156.7, 155.1 (C=O Cbz, C=O Boc, CAr-O), 136.6, 130.1, 129.4, 128.7, 128.4, 128.3, 126.9, 121.2, 112.2, 79.4 (C(CH3)3 Boc), 69.1, 67.7, 67.0, 65.7, 41.0, 40.9, 40.8, 39.6, 39.4, 36.7, 31.0, 28.6 (3 x CH3 Boc), 27.1. LC-HRMS (ESI) calc. for C30H40N2O6Na [M+Na]+: 547.2779; found: 547.2799.
Step a1 Benzyl (2-(2-(((7-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-7-azaspiro[3.5]nonan-2-yl)oxy)methyl)phenoxy)ethyl)carbamate 1. Boc deprotection. In analogy to the procedure described in Example 1 a1, step (1), tert- Butyl 2-((2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)-7-azaspiro[3.5]nonane-7- carboxylate (BB 13) (52.5 mg, 0.10 mmol) was dissolved in DCM (0.7 mL) at 0 °C and TFA (0.11 mL, 1.40 mmol) was added. The reaction mixture was stirred at that temperature until Boc deprotection was complete (30 min, LC-MS monitoring). The reaction was diluted with toluene (3.00 mL), and coevaporated with toluene (3.00 mL) under reduced pressure twice. The trifluoroacetate salt of the free amine was used in the next step without further purification. 2. Urea coupling. Triphosgene (CAS RN 32315-10-9, 53.8 mg, 0.10 mmol) and NaHCO3 (33.6 mg, 0.08 mmol) were suspended in DCM (1.0 mL) at 0 °C. The deprotected amine derivative of Benzyl (2-(2-(((7-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine- 6-carbonyl)-7-azaspiro[3.5]nonan-2-yl)oxy)methyl)phenoxy)ethyl)carbamate obtained in step a1, 1) was dissolved in anhydrous DCM (1.5 mL) and added dropwise to the triphosgene mixture. The mixture was allowed to warm to r.t. and stirred overnight. The filtrate of this solution was then added dropwise at 0 °C to a solution of (4aR,8aS)-hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one (CAS RN 2377107-31-6, 15.6 mg, 0.10 mmol) and DIPEA (70.0 µL, 0.40 mmol) in DCM (1.0 mL). The mixture was allowed to warm to r.t. and stirred for an additional 3 h. The mixture was concentrated in vacuo and purified by RP- HPLC (25 to 75% ACN in H2O with 0.1% TFA). To afford the title compound (23.6 mg, 39.0 µmol, 39%).1H NMR (300 MHz, MeOD) δ 7.37 – 7.19 (m, 7H), 6.91 (td, J = 8.3, 1.4 Hz, 2H), 5.08 (s, 2H, OCH2), 4.42 (s, 2H, OCH2), 4.24 – 4.00 (m, 5H), 3.96 (d, J = 3.0 Hz, 1H), 3.59 (dd, J = 12.7, 5.1 Hz, 1H), 3.52 (t, J = 5.4 Hz, 2H), 3.44 – 3.32 (m, 2H), 3.17 – 2.89 (m, 6H), 2.21 – 2.09 (m, 2H), 1.92 – 1.82 (m, 2H), 1.77 – 1.64 (m, 2H), 1.56 – 1.41 (m, 4H).13C NMR (75 MHz, CDCl3) δ 171.2, 165.5, 158.9, 158.1 (C=O urea, C=O amide, C=O Cbz, CAr-O), 138.4, 130.9, 130.3, 129.5, 129.0, 128.7, 127.9, 121.8, 112.8, 70.6, 70.3, 68.2, 67.5, 66.2, 50.4, 45.2, 45.1, 42.9, 41.6, 40.6, 40.4, 37.7, 32.3, 30.3. LC-HRMS (ESI) calc. for C33H42N4O7Na [M+Na]+: 629.2946; found: 629.2961. If not indicated otherwise the following examples were synthesized in analogy to the synthesis described for Example 15 using suitable building blocks.
Example 17 Benzyl (R)-(2-(2-(((1-(3-(2-oxooxazolidin-4-yl)propanoyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate
Synthesis of the building block: 3-[(4R)-2-Oxooxazolidin-4-yl]propanoic acid (3 steps) Step 1) Methyl (S)-4-((tert-butoxycarbonyl)amino)-5-hydroxypentanoate To a solution of (R)-2-((tert-butoxycarbonyl)amino)-5-methoxy-5-oxopentanoic acid (1 g, 3.83 mmol, CAS: 76379-01-6) in THF (15 mL) at -10 °C was added N-methylmorpholine (421 µL, 3.83 mmol), followed by ethyl chloroformate (368 µL, 3.83 mmol) and the reaction mixture was stirred at this temperature for 10 minutes. Addition of NaBH4 (434 mg, 11.5 mmol) in one portion did not cause a temperature increase. MeOH (35 mL) was added dropwise between -1°C and 17 °C over 30 min. Stirring was continued in an ice bath for 1
h. A 1 M aqueous KHSO4 sol. (40 mL) was added dropwise to the reaction mixture and then the organic solvents were evaporated under reduced pressure. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed with aqueous 1 M KHSO4 solution and sat. aqueous NaHCO3 solution, dried over MgSO4, filtered, treated with silica gel and evaporated under reduced pressure. The crude compound was purified by silica gel chromatography using a MPLC system eluting with a gradient of n-heptane : ethyl acetate (100 : 0 to 30 : 70) to get the title compound as a colorless oil (0.70 g, 66 %). MS (ESI): m/z = 192.1 [M+H]+. Step 2) Methyl (R)-3-(2-oxooxazolidin-4-yl)propanoate To a solution of methyl (S)-4-((tert-butoxycarbonyl)amino)-5-hydroxypentanoate (690 mg, 2.79 mmol, 1.0 equiv) in THF (8.8 mL) was added dropwise thionyl chloride (611 µL, 8.37 mmol,3.0 equiv) and the solution was stirred at r.t. for 3 h. Silica gel was added and the reaction mixture was evaporated under reduced pressure. The compound was purified by silica gel chromatography using a MPLC system eluting with a gradient of n-heptane : ethyl acetate (100 : 0 to 0 : 100) to afford the title compound as a colorless oil (404 mg, 79 %). MS (ESI): m/z = 174.1 [M+H]+. Step 3) (R)-3-(2-Oxooxazolidin-4-yl)propanoic acid To a solution of methyl (S)-3-(2-oxooxazolidin-4-yl)propanoate (400 mg, 2.31 mmol, 1.0 equiv) in 1,4-dioxane (2 mL) and water (2 mL) was added lithium hydroxide monohydrate (107 mg, 2.54 mmol, 1.1 equiv) and the reaction mixture was stirred at r.t. for 2 h. 1,4- Dioxane was evaporated and aqueous HCl (2.54 mL, 2.54 mmol, 1.1 equiv) was added dropwise to the solution. The aqueous layer was extracted five times with ethyl acetate. The combined organic layers were dried over MgSO4 , filtered and evaporated to get the title compound as a colorless solid (330 mg, 86 %). MS (ESI): m/z = 160.1 [M+H]+. Step a2 (R)-(2-(2-(((1-(3-(2-oxooxazolidin-4-yl)propanoyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate (R)-3-(2-oxooxazolidin-4-yl)propanoic acid (12.7 mg, 0.08 mmol) was dissolved in THF/ACN 1:1 (1.60 mL) and then DIPEA (42.0 µL, 0.24 mmol) followed by HATU (36.5 mg, 96.0 µmol) were added. After stirring for 10 min the deprotected amine derivative of tert-butyl 3-(((2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1- carboxylate BB1 (38.7 mg, 0.08 mmol, prepared as described for Example 1, step 1, Boc deprotection) was added. The mixture was stirred at r.t. overnight and then the mixture was directly diluted with ACN/H2O and purified by RP-HPLC (15-85% ACN in H2O with 0.1%
TFA) to afford the title compound (16.3 mg, 0.032 mmol, 40%). LC-HRMS (ESI) calc. for C27H34N3O7 [M+H]+: 512.2389; found: 512.2391. Example 18 Benzyl (2-(2-(((1-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate
In analogy to the procedure described in Example 17, step a2, tert-butyl 3-(((2-(2- (((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carboxylate BB1 was reacted with 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylic acid (CAS RN: 134997-87-8) to afford the title compound (22.3 mg, 0.0.41 mmol, 50%). LC-HRMS (ESI) calc. for C30H32N3O7 [M+H]+: 546.2235; found: 546.2239. Example 19 2-(6-(2-(2-((7-nitro-1l2,3l2-benzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)benzyl)-2- azaspiro[3.3]heptane-2-carbonyl)-7-oxa-2,5-diazaspiro[3.4]octan-6-one
Step b 2-(6-(2-(2-aminoethoxy)benzyl)-2-azaspiro[3.3]heptane-2-carbonyl)-7-oxa-2,5- diazaspiro[3.4]octan-6-one
A mixture of 20% tBuOH in EtOAc (HPLC grade) was purged with N2 for at least 15 min and kept under N2 atmosphere on a closed vial. In a pear-shaped flask, the starting material
benzyl (2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)ethyl)carbamate (Example 13, 16.0 mg, 0.03 mmol) was dissolved in the previously prepared solvent mixture and purged with N2 for 10 min. Next, Palladium on Carbon (10 mol%) was added to the mixture and further purged with N2 for additional 15 min. Using a H2-filled balloon, the reaction was then carried with constant bubbling of H2 through the solution until completion (LC-MS monitoring). Solvent mixture levels were kept at 1-2 mL by adding small amounts of the previously prepared N2-purged solvent mixture when needed. Palladium on carbon was removed from reaction the mixture by filtration with a PTFE syringe filter (pore size: 0.45 μm) using ACN and water to wash the filter. The crude was lyophilized and the obtained title compound was used in next step (step c) without further purification.LC-MS [M+H]+: 400.9. Step c 2-(6-(2-(2-((7-nitro-1l2,3l2-benzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)benzyl)-2- azaspiro[3.3]heptane-2-carbonyl)-7-oxa-2,5-diazaspiro[3.4]octan-6-one 2-(6-(2-(2-aminoethoxy)benzyl)-2-azaspiro[3.3]heptane-2-carbonyl)-7-oxa-2,5- diazaspiro[3.4]octan-6-one (12.0 mg, 0.03 mmol) from step c) was dissolved in MeOH (0.75 mL) and trimethylamine (13.0 µL, 0.09 mmol) was added. Next, a solution of 4-fluoro-7- nitrobenz-2-oxa-1,3-diazole (CAS RN 29270-56-2, 11.0 mg, 0.06 mmol) in MeOH (0.3 mL) was added dropwise. The reaction was stirred in the dark for 3.5 h. Next, the solvent was removed in vacuo at 20 °C and the reaction was purified through RP-HPLC 15-85% ACN in H2O with 0.1% TFA to afford the title product (3.19 mg, 6.0 µmol, 19%).1H NMR (600 MHz, CD3CN) δ 8.53 (d, J = 8.8 Hz, 1H), 7.16 (td, J = 7.8, 1.7 Hz, 1H), 7.06 (dd, J = 7.4, 1.7 Hz, 1H), 6.92 (dd, J = 8.3, 1.1 Hz, 1H), 6.87 (td, J = 7.4, 1.1 Hz, 1H), 6.51 – 6.39 (m, 2H), 4.47 (s, 2H), 4.27 (t, J = 5.0 Hz, 2H), 4.05 – 3.83 (m, 6H), 3.67 (s, 2H), 3.60 (s, 2H), 2.55 (d, J = 7.5 Hz, 2H), 2.26 (p, J = 7.8 Hz, 1H), 2.03 – 1.96 (m, 2H), 1.75 – 1.68 (m, 2H). 13C NMR (151 MHz, CD3CN) δ 162.19, 157.44, 156.29, 144.81, 137.33, 130.22, 129.00, 127.24, 120.80, 111.37, 74.18, 65.81, 62.84, 62.43, 61.60, 54.21, 38.31, 36.10, 34.53, 29.56. LC-HRMS (ESI) calc. for C27H30N7O7 [M+H]+: 564.2201; found: 564.2192. If not indicated otherwise the following examples were synthesized in analogy to the synthesis described for Example 19 using suitable building blocks.
Example 26 2-(7-(Dimethylamino)-3-(dimethyliminio)-5,5-dimethyl-3,5-dihydrodibenzo[b,e]silin- 10-yl)-4-((5-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-yl)methyl)phenoxy)pentyl)carbamoyl)benzoate
Step b 2-(6-(2-((5-aminopentyl)oxy)benzyl)-2-azaspiro[3.3]heptane-2-carbonyl)-7-oxa- 2,5-diazaspiro[3.4]octan-6-one
In analogy to the procedure described in example 19 b), benzyl (5-(2-((2-(6-oxo-7-oxa-2,5- diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- ylidene)methyl)phenoxy)pentyl)carbamate (Example 14) was treated with hydrogen and palladium on carbon to afford the title compound, which used in next step (step c) without further purification. LC-MS [M+H]+: 442.9. Step c 2-(7-(Dimethylamino)-3-(dimethyliminio)-5,5-dimethyl-3,5- dihydrodibenzo[b,e]silin-10-yl)-4-((5-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2- carbonyl)-2-azaspiro[3.3]heptan-6-yl)methyl)phenoxy)pentyl)carbamoyl)benzoate 2-(6-(2-((5-aminopentyl)oxy)benzyl)-2-azaspiro[3.3]heptane-2-carbonyl)-7-oxa-2,5- diazaspiro[3.4]octan-6-one (8.96 mg, 0.02 mmol) was dissolved in ACN with 10% DMF (0.90 mL) at 0 °C, then the 2-(7-(dimethylamino)-3-(dimethyliminio)-5,5-dimethyl-3,5- dihydrodibenzo[b,e]silin-10-yl)-4-(((2,5-dioxopyrrolidin-1-yl)oxy)carbonyl)benzoate (CAS RN 1426090-09-6, 5.00 mg, 9.0 µmol) followed by DIPEA (9.0 µL, 7.0 µmol) were added. The reaction was stirred at room in the dark for approximately 4h (LC-MS monitoring of the reaction). Then diluted with H2O/ACN and freeze dried. The crude was purified by RP-HPLC H2O/ACN with 0.1% TFA 25 to 75% in 30 min to afford the target product (6.0 mg, 7.0 µmol, 76%).1H NMR (600 MHz, MeOD) δ 8.33 (d, J = 8.2 Hz, 1H), 8.14 (dd, J = 8.2, 1.8 Hz, 1H), 7.74 (d, J = 1.7 Hz, 1H), 7.36 (d, J = 2.9 Hz, 2H), 7.13 (td, J = 7.8, 1.7 Hz, 1H), 7.04 (dd, J = 7.4, 1.7 Hz, 1H), 7.02 – 6.99 (m, 2H), 6.88 (dd, J = 8.2, 1.1 Hz, 1H), 6.83 (td, J = 7.3, 1.0 Hz, 1H), 6.77 (dd, J = 9.6, 2.9 Hz, 2H), 4.53 (s, 2H, OCH2), 4.07 (s, 4H, OCH2), 4.00 (t, J = 6.1 Hz, 2H), 3.93 (s, 2H), 3.84 (s, 2H), 3.47 (t, J = 7.1 Hz, 2H), 3.32 (s, 12H, 4 x N-CH3), 2.64 (d, J = 7.4 Hz, 2H), 2.44 (p, J = 7.7 Hz, 1H, CH spirocycle), 2.22 – 2.16 (m, 2H, CH-CH2-C spirocycle), 1.88 (ddd, J = 10.5, 7.9, 2.8 Hz, 4H, CH-CH2-C spirocycle, -CH2- alkyl), 1.74 (p, J = 7.2 Hz, 2H, -CH2- alkyl), 1.67 – 1.59 (m, 2H, -CH2- alkyl), 0.68 (s, 3H, Si-CH3), 0.62 (s, 3H, Si-CH3). 13C NMR (151 MHz, MeOD) δ 166.6, 162.3, 159.0, 156.8 (C=O urea, C=O carbamate, COO-, CAr-O), 129.7, 128.5, 127.4, 126.9, 120.1, 119.8, 113.8, 110.9, 74.2 (OCH2), 67.2 (OCH2), 63.0, 62.4, 61.8, 54.4 (-C- carbamate spirocycle), 39.8, 39.6, 38.2, 36.0, 34.7 (-C- spirocycle), 29.7 (CH spirocycle), 28.9, 28.8 (-CH2- alkyl), 23.5 (-CH2- alkyl), -2.20 (Si-CH3), -3.09 (Si-CH3). LC-HRMS (ESI) calc. for C51H60N6O7Si [M+H]+: 897.4366; found: 897.4357. If not indicated otherwise the following examples were synthesized in analogy to the synthesis described for Example 26 using suitable building blocks.
Example 32 is a regioisomeric mixture of 5- and 6-carboxytetramethylrhodamine derivatives that was obtained in one reaction. HPLC purification allowed to separate a fraction ofthe 5- carboxytetramethylrhodamine derivative (example 33) from the mixture. The respective 6- carboxytetramethylrhodamine derivative could not be obtained in pure form. The same considerations apply to examples 34 and 35 and 36 and 37, respectively. Example 38 was obtained as 5- and 6-carboxytetramethylrhodamine derivative regioisomeric mixture.
Example 39 Ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)benzoate
Step d tert-butyl 3-((3-(ethoxycarbonyl)phenoxy)methyl)azetidine-1-carboxylate (BB15)
In analogy to the procedure described in Example 1 d), ethyl 3-hydroxy benzoate (CAS RN 7781-98-8) was reacted with tert-butyl 3-(bromomethyl)azetidine-1-carboxylate (CAS RN 253176-93-1) to afford the title compound (18.0 mg, 0.05 mmol, 18%). LC-MS (ESI) [M+Na]+. [M+Na]+: 338.1 Step a1 Ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)benzoate In analogy to the procedure described in Example 1, a1), (4aR,8aS)-3-oxooctahydro-2H- pyrido[4,3-b][1,4]oxazin-6-ium (2S,3S)-3-carboxy-2,3-bis((4- methylbenzoyl)oxy)propanoate salt (CAS RN 2624363-49-9, 66.7 mg, 0.09 mmol) was reacted with the deprotected amine derivative of tert-butyl 3-((3- (ethoxycarbonyl)phenoxy)methyl)azetidine-1-carboxylate BB15 (33.5 mg, 0.10 mmol prepared as described for Example 1, step 1, Boc deprotection) to afford the title compound (16.3 mg, 0.032 mmol, 40%). LC-MS (ESI) [M+H]+: 418.2. If not indicated otherwise the following examples were synthesized in analogy to the synthesis described for Example 39 using suitable building blocks.
Example 42 tert-Butyl (2-(3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)benzamido)ethyl)carbamate
Step k 1. Ester hydrolysis. Ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3- b][1,4]oxazine-6-carbonyl)azetidin-3-yl)oxy)benzoate (Example 40, 12.5 mg, 0.03 mmol) was dissolved in THF/MeOH/H2O 3:1:1 (0.2 mL) and lithium hydroxide (LiOH, 2,15 mg, 0.09 mmol) was added. The reaction was stirred at room temperature until completion (ca. 2h). The reaction was quenched by diluting with ethyl acetate (1.0 mL), extracted with aq. sn. 1 M HCl (0.5 mL), and washed with brine (0.5 mL). The organic layer was dried over MgSO4, filtrated, and solvent was removed in vacuo. The carboxylic acid 3-((1-((4aR,8aS)- 3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3-yl)oxy)benzoic acid was used in the next step without further purification. 2. Amide coupling. 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)benzoic acid crude obtained in step 1 from Ethyl 3-((1- ((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)oxy)benzoate (Example 40) was dissolved in DMF (0.43 mL) and DIPEA (16.0 µL, 0.09 mmol) followed by 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU, CAS RN 148893-10-1, 13.7 mg, 0.04 mmol) were added. The mixture was stirred for 10 min, and then tert-butyl (2-aminoethyl)carbamate (CAS RN 57260-73-8, 5.28 mg, 0.03 mmol) was added. The mixture was stirred at room temperature for 18 h, then diluted with ethyl acetate (1.0 mL, washed with brine (0.5 mL), dried over Na2SO4, filtrated and concentrated under reduced pressure. The crude was purified by RP-HPLC H2O/ACN with 0.1% TFA 25 to 75% to afford the title compound (5.0 mg, 0.01 mmol, 32%). LC-HRMS (ESI) calc. for C25H36N2O7 [M+H]+: 518.2609; found: 518.2601. Example 43 tert-Butyl (2-(2-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)benzamido)ethyl)carbamate
In analogy to the procedure described in Example 42, k) Ethyl 2-((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3-yl)methoxy)benzoate (Example 41) was subjected to ester hydrolysis (step k, 1) and then reacted with tert-butyl (2-aminoethyl)carbamate (CAS RN 57260-73-8, 5.28 mg, 0.03 mmol) to afford the title compound (5.0 mg, 9.0 µmol, 55%). LC-MS (ESI) [M+H]+: 532.2. Example 44 (4aR,8aS)-6-(3-((benzyloxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one
Step l tert-Butyl 3-((benzyloxy)methyl)azetidine-1-carboxylate
tert-Butyl 3-(hydroxymethyl)azetidine-1-carboxylate (CAS RN 142253-56-3, 103 mg, 0.55 mmol) and sodium hydride 60% dispersion in mineral oil (CAS RN 7646-69-7, 55.0 mg, 1.38 mmol) were suspended in anhydrous DMF (2.0 mL) at 0 °C for 15 min, or until no gas evolution was seen. Then benzyl bromide (CAS RN 100-39-0, 0.16 mL, 1.38 mmol) was added. The reaction was allowed to warm up to room temperature and was stirred for 16 h. The mixture was diluted with dichloromethane (10.0 mL), neutralized with acetic acid, extracted with aq. sat. NaHCO3 (10 mL) and washed with water (10 mL). The organic layer was dried over MgSO4, filtrated, and concentrated in vacuo. The crude was purified via silica gel flash chromatography using ethyl acetate in cyclohexane 0 to 80% as eluent, to afford the title compound (120 mg, 0.43 mmol, 77%).1H NMR (300 MHz, CDCl3) δ 7.40 – 7.26 (m, 5H), 3.99 (t, J = 8.5 Hz, 2H), 3.66 (dd, J = 8.7, 5.3 Hz, 2H), 3.58 (d, J = 6.8 Hz, 2H), 2.88 – 2.67 (m, 1H), 1.43 (s, 9H). LC-MS [M+Na]+: 300.1. step a1 (4aR,8aS)-6-(3-((benzyloxy)methyl)azetidine-1-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one
In analogy to the procedure described in Example 1, a1), tert-Butyl 3- ((benzyloxy)methyl)azetidine-1-carboxylate was reacted with 4aR,8aS)-3-oxooctahydro- 2H-pyrido[4,3-b][1,4]oxazin-6-ium (2S,3S)-3-carboxy-2,3-bis((4- methylbenzoyl)oxy)propanoate salt (CAS RN 2624363-49-9) to afford the title compound. LC-MS (ESI) [M+H]+: 360.1. Example 45 (4aR,8aS)-6-(6-(benzyloxy)-2-azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one
Step l tert-Butyl 6-(benzyloxy)-2-azaspiro[3.3]heptane-2-carboxylate
In analogy to the procedure described in Example 44 l), tert-butyl 6-hydroxy-2- azaspiro[3.3]heptane-2-carboxylate (CAS RN 1147557-97-8) was reacted with benzyl bromide (CAS RN 100-39-0) to afford the title compound. 1H NMR (300 MHz, CDCl3) δ 7.41 – 7.27 (m, 5H), 4.39 (s, 2H), 4.02 – 3.75 (m, 5H), 2.46 (ddd, J = 9.8, 6.8, 3.0 Hz, 2H), 2.14 (ddd, J = 10.1, 7.3, 3.0 Hz, 2H), 1.42 (s, 9H). Step a1 (4aR,8aS)-6-(6-(benzyloxy)-2-azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one In analogy to the procedure described in Example 1, a1), tert-Butyl 6-(benzyloxy)-2- azaspiro[3.3]heptane-2-carboxylate was reacted with 4aR,8aS)-3-oxooctahydro-2H- pyrido[4,3-b][1,4]oxazin-6-ium (2S,3S)-3-carboxy-2,3-bis((4- methylbenzoyl)oxy)propanoate salt (CAS RN 2624363-49-9) to afford the title compound. LC-MS (ESI) [M+H]+: 386.2.
Example 46 (4aR,8aS)-6-(3-(phenoxymethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one
In analogy to the procedure described in Example 1 a1) tert-butyl 3- (phenoxymethyl)azetidine-1-carboxylate (obtained from phenol, CAS RN 108-95-2, and tert-butyl 3-(bromomethyl)azetidine-1-carboxylate, CAS RN 253176-93-1, in analogy to example 1d) was reacted with 4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazin-6- ium (2S,3S)-3-carboxy-2,3-bis((4-methylbenzoyl)oxy)propanoate salt (CAS RN 2624363- 49-9) to afford the title compound. LC-MS (ESI) [M+H]+: 346.1 Building block synthesis BB2 tert-Butyl 3-((2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)azetidine-1- carboxylate In analogy to the procedure described in Example 1 g), tert-butyl 3-hydroxy-azetidine-1- carboxylate (CAS RN 141699-55-0, 125 mg, 0.72 mmol) was reacted with benzyl (2-(2- (bromomethyl)phenoxy)ethyl)carbamate (see Example 1, 131 mg, 0.36 mmol) to afford the title compound (101 mg, 0.22 mmol, 61%). 1H NMR (300 MHz, CDCl3) δ 7.41 – 7.27 (m, 7H), 6.97 (t, J = 7.4 Hz, 1H), 6.86 (d, J = 8.1 Hz, 1H), 5.43 (s, 1H, NH-Cbz), 5.11 (s, 2H, OCH2-Ar), 4.46 (s, 2H, OCH2 Cbz), 4.31 (dq, J = 10.8, 5.1 Hz, 1H, CH azetidine), 4.10 (t, J = 5.0 Hz, 2H), 4.07 – 3.97 (m, 2H), 3.92 – 3.81 (m, 2H), 3.62 (q, J = 5.4 Hz, 2H, OCH2CH2- NHCbz), 1.42 (d, J = 1.0 Hz, 9H, CH3 Boc).13C NMR (75 MHz, CDCl3) δ 156.6, 156.5 (C=O Cbz, C=O urea), 136.6, 130.1, 129.7, 128.7, 128.4, 128.3, 121.3, 112.0 (C-Ar), 79.7 (CH Boc), 67.6, 67.0, 66.5 (3 x OCH2), 56.65, 40.8 (CH2-NHCbz), 28.5 (CH3 Boc). LC- HRMS (ESI) calc. for C25H33N2O6 [M+H]+: 457.2333; found: 457.2320. BB3
tert-Butyl 6-((2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)-2- azaspiro[3.3]heptane-2-carboxylate
In analogy to the procedure described in Example 1 g), benzyl (2-(2- (bromomethyl)phenoxy)ethyl)carbamate (see Example 1) was reacted with tert-butyl 6- hydroxy-2-azaspiro[3.3]heptane-2-carboxylate (CAS RN 1147557-97-8), to afford the title compound (48.5 mg, 0.098 mmol, 65%).1H NMR (300 MHz, CDCl3) δ 7.39 – 7.21 (m, 7H), 6.95 (td, J = 7.5, 1.0 Hz, 1H), 6.84 (d, J = 8.5 Hz, 1H), 5.54 (s, 1H, NHCbz), 5.10 (s, 2H, OCH2), 4.40 (s, 2H, OCH2), 4.10 (t, J = 5.0 Hz, 2H), 3.93 – 3.72 (m, 5H, CH spirocycle, 2 x NCH2 spirocycle), 3.61 (q, J = 5.3 Hz, 2H, CH2NHCbz), 2.41 – 2.28 (m, 2H, C-CH2-CH spirocycle), 2.14 – 1.95 (m, 2H, C-CH2-CH spirocycle), 1.43 (s, 9H, 3 x CH3 Boc).13C NMR (75 MHz, CDCl3) δ 156.7, 156.6, 156.2 (C=O Cbz, C=O Boc, CAr-O), 136.5, 130.1, 129.5, 128.7, 128.5, 128.4, 126.6, 121.2, 112.1, 79.4 (C(CH3)3 Boc), 68.1, 67.6, 67.0, 65.8, 61.8, 60.5, 41.2, 40.7 (CH2NHCz, 2 x C-CH2-CH spirocycle), 30.1 (-C- spirocycle), 28.5 (3 x CH3 Boc). LC-HRMS (ESI) calc. for C28H36N2O6Na [M+Na]+: 519.2466; found: 519.2450. BB4 tert-Butyl 7-((2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)-2- azaspiro[3.5]nonane-2-carboxylate
In analogy to the procedure described in Example 1 g), benzyl (2-(2- (bromomethyl)phenoxy)ethyl)carbamate (see Example 1) was reacted with tert-butyl 7- hydroxy-2-azaspiro[3.5]nonane-2-carboxylate (CAS RN 1363383-18-9), to afford the title compound (18.0 mg, 0.05 mmol, 26%).1H NMR (300 MHz, CDCl3) δ 7.35 (s, 7H), 7.02 – 6.77 (m, 2H), 5.41 (s, 1H, NHCbz), 5.10 (s, 2H, OCH2), 4.53 (s, 2H, OCH2), 4.08 (t, J = 5.0 Hz, 2H), 4.04 – 3.93 (m, 1H), 3.69 – 3.41 (m, 7H), 1.94 – 1.72 (m, 4H), 1.54 – 1.32 (m, 12H). 13C NMR (75 MHz, CDCl3) δ 156.6, 156.5, 156.2 (C=O Cbz, C=O Boc, CAr-O), 136.4, 129.5, 128.9, 128.6, 128.5, 128.2, 128.1, 127.9, 127.4, 121.1, 111.7, 79.2 (C(CH3)3 Boc), 67.3, 66.9, 65.2, 59.0, 40.7 (CH2NHCbz), 34.5, 33.0, 28.5, 28.2 (3 x CH3 Boc). LC- HRMS (ESI) calc. for C30H40N2O6Na [M+Na]+: 547.2779; found: 547.2774.
BB5 tert-Butyl 3-(((3-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)azetidine- 1-carboxylate
Step d Ethyl 3-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzoate
In analogy to the procedure described in Example 1 d), ethyl 3-hydroxy benzoate (CAS RN 7781 98 8) was reacted with 2-(((benzyloxy)carbonyl)amino)ethyl 4- methylbenzenesulfonate (CAS RN 93407-96-6) to afford the title compound (1.05 g, 3.05 mmol, 61%). 1H NMR (300 MHz, CDCl3) δ 7.66 (dt, J = 7.7, 1.3 Hz, 1H), 7.54 (dd, J = 2.7, 1.5 Hz, 1H), 7.40 – 7.27 (m, 6H), 7.12 – 7.02 (m, 1H), 5.22 (s, 1H, NH-Cbz), 5.12 (s, 2H, OCH2CH3), 4.37 (q, J = 7.1 Hz, 2H, OCH2), 4.09 (t, J = 5.1 Hz, 2H, OCH2), 3.63 (q, J = 5.4 Hz, 2H, CH2NHCbz), 1.39 (t, J = 7.1 Hz, 3H, OCH2CH3). 13C NMR (75 MHz, CDCl3) δ 166.5, 158.5, 156.5 (C=O CO2Et, C=O Cbz, CAr-O), 136.5, 132.1, 129.6, 128.7, 128.4, 128.3, 122.6, 119.7, 114.9, 67.3 (OCH2), 67.1 (OCH2), 61.3 (OCH2), 40.7 (CH2NHCbz), 14.5 (CH3). LC-HRMS (ESI) calc. for C19H22NO5 [M+H]+: 366.1492; found: 366.1508. Step e Benzyl (2-(3-(hydroxymethyl)phenoxy)ethyl)carbamate
In analogy to the procedure described in Example 1 e), ethyl 3-(2- (((benzyloxy)carbonyl)amino)ethoxy)benzoate was reacted to afford the title compound (115 mg, 0.38 mmol, 66%).1H NMR (300 MHz, CDCl3) δ 7.43 – 7.16 (m, 6H), 7.00 – 6.85 (m, 2H), 6.87 – 6.70 (m, 1H), 5.11 (s, 2H, O-CH2-), 4.66 (s, 2H, O-CH2-), 4.04 (t, J = 5.1 Hz, 2H, -OCH2CH2NHCbz), 3.60 (d, J = 5.3 Hz, 2H, -OCH2CH2NHCbz). 13C NMR (75 MHz, CDCl3) δ 158.8, 156.6 (C=O Cbz, CAr-O), 142.8, 136.5, 129.8, 128.7, 128.32, 128.28, 119.7, 113.8, 112.9 (C-Ar), 67.01 (O-CH2-), 66.96 (O-CH2-), 65.2 (O-CH2-), 40.7 (-CH2- NHCbz). LC-HRMS (ESI) calc. for C17H20NO4 [M+H]+: 302.1387; found: 302.1373. Step f Benzyl (2-(3-(bromomethyl)phenoxy)ethyl)carbamate
In analogy to the procedure described in Example 1 f), benzyl (2-(3- (hydroxymethyl)phenoxy)ethyl)carbamate was reacted to afford the title compound (503 mg, 1.38 mmol, 63%).1H NMR (300 MHz, CDCl3) δ 7.42 – 7.22 (m, 6H), 7.03 – 6.97 (m, 1H), 6.95 – 6.90 (m, 1H), 6.88 – 6.79 (m, 1H), 5.24 (s, 1H, NHCbz), 5.13 (s, 2H, OCH2), 4.46 (s, 2H, CH2Br), 4.06 (t, J = 5.1 Hz, 2H, OCH2), 3.63 (q, J = 5.4 Hz, 2H, CH2NHCbz).13C NMR (75 MHz, CDCl3) δ 158.8, 156.5 (C=O Cbz, CAr-O), 139.4, 139.2, 136.5, 130.1, 128.7, 128.33, 128.29, 121.9, 121.4, 115.2, 114.7, 114.7, 67.0 (2 x OCH2), 40.7 (CH2NHCbz), 33.4 (CH2Br). LC-HRMS (ESI) calc. for C17H19BrNO3 [M+H]+: 366.0524; found: 366.0551. Step g tert-Butyl 3-(((3-(2- (((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carboxylate In analogy to the procedure described in Example 1 g), Benzyl (2-(3- (bromomethyl)phenoxy)ethyl)carbamate was reacted with tert-butyl 3- (hydroxymethyl)azetidine-1-carboxylate (CAS RN 142253-56-3) to afford the title compound (85.0 mg, 0.18 mmol, 55%).1H NMR (300 MHz, CDCl3) δ 7.40 – 7.20 (m, 6H), 7.01 – 6.74 (m, 3H), 5.31 – 5.06 (m, 3H, NHCbz, OCH2), 4.70 – 4.42 (m, 3H), 4.07 – 3.91 (m, 4H), 3.74 – 3.51 (m, 5H), 2.88 – 2.69 (m, 1H, CH azetidine), 1.43 (d, J = 1.2 Hz, 9H, 3 x CH3 Boc). LC-HRMS (ESI) calc. for C26H34N2O6Na [M+Na]+: 493.2309; found: 493.2312 BB6 tert-Butyl 3-((3-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)azetidine-1- carboxylate
In analogy to the procedure described for BB7, Benzyl (2-(3- (bromomethyl)phenoxy)ethyl)carbamate was reacted with tert-butyl 3-hydroxyazetidine-1- carboxylate (CAS RN 141699-55-0), to afford the title compound (55.1 mg, 0.12 mmol, 55%). LC-HRMS (ESI) calc. for C25H33N2O6 [M+H]+: 457.2333; found: 457.2328. BB7 tert-Butyl 6-((3-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)-2- azaspiro[3.3]heptane-2-carboxylate
In analogy to the procedure described for BB7, Benzyl (2-(3- (bromomethyl)phenoxy)ethyl)carbamate was reacted with tert-butyl 6-hydroxy-2- azaspiro[3.3]heptane-2-carboxylate (CAS RN 1147557-97-8) to afford the title compound (21.0 mg, 0.042 mmol, 28%).1H NMR (300 MHz, CDCl3) δ 7.36 (d, J = 4.9 Hz, 5H), 7.22 (d, J = 7.8 Hz, 1H), 6.93 – 6.74 (m, 3H), 5.11 (s, 2H, OCH2), 4.35 (s, 2H, OCH2), 4.04 (t, J = 5.1 Hz, 2H, OCH2), 4.01 – 3.78 (m, 5H, N-CH2-C spirocycle, CH spirocycle), 3.61 (q, J = 5.4 Hz, 2H, CH2NHCbz), 2.47 (m, 2H, C-CH2-CH spirocycle), 2.14 (m, 2H, C-CH2-CH spirocycle), 1.42 (s, 9H, 3 x CH3 Boc).13C NMR (75 MHz, CDCl3) δ 158.7, 156.5, 156.3 (C=O Cbz, C=O Boc, CAr-O), 139.9, 136.5, 129.7, 128.7, 128.34, 128.30, 120.6, 113.8, 79.5 (C(CH3)3 Boc), 70.1, 68.1, 67.0, 61.9, 60.6, 41.2, 40.7, 30.3 (3 x CH3 Boc), 28.5 (-C- spirocycle). LC-HRMS (ESI) calc. for C28H37N2O6 [M+H]+: 497.2646; found: 497.2636. BB8 tert-Butyl 3-(((2-(3- (((benzyloxy)carbonyl)amino)propoxy)benzyl)oxy)methyl)azetidine-1-carboxylate
Step d Ethyl 2-(3-(((benzyloxy)carbonyl)amino)propoxy)benzoate
In analogy to the procedure described in Example 1d), ethyl salicylate (CAS RN 118-61-6) was reacted with 3-(((benzyloxy)carbonyl)amino)propyl 4-methylbenzenesulfonate (CAS RN 68076-37-9) to afford the title compound (3.98 g, 11.2 mmol, 82%).1H NMR (300 MHz, CDCl3) δ 7.85 (dd, J = 7.8, 1.8 Hz, 1H), 7.56 – 7.20 (m, 6H), 7.06 – 6.87 (m, 2H), 6.54 (s, 1H, NHCbz), 5.11 (s, 2H, OCH2), 4.24 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.13 (t, J = 5.5 Hz, 2H, OCH2), 3.57 – 3.40 (m, 2H, CH2NHCbz), 2.06 (p, J = 5.6 Hz, 2H, -CH2-), 1.29 (t, J = 7.1 Hz, 3H, OCH2CH3). 13C NMR (75 MHz, CDCl3) δ 166.0, 158.7, 157.0 (C=O CO2Et, C=O Cbz, CAr-O), 137.1, 133.9, 132.0, 128.4, 128.0, 127.9, 120.4, 119.7, 112.7, 68.2
(OCH2), 66.5 (OCH2), 61.0 (OCH2), 39.9 (CH2NHCbz), 29.1 (-CH2-), 14.4 (CH3). LC- HRMS (ESI) calc. for C20H23NO5Na [M+Na]+: 380.1468; found: 380.1474. Step e Benzyl (3-(2-(hydroxymethyl)phenoxy)propyl)carbamate
In analogy to the procedure described in Example 1 e), Ethyl 2-(3- (((benzyloxy)carbonyl)amino)propoxy)benzoate was reacted to afford the title compound (2.35 g, 7.45 mmol, 98%).1H NMR (300 MHz, CDCl3) δ 7.39 – 7.19 (m, 7H), 6.94 (td, J = 7.4, 1.1 Hz, 1H), 6.83 (d, J = 8.1 Hz, 1H), 5.08 (s, 2H, -OCH2-), 4.66 (s, 2H, -OCH2-), 4.03 (td, J = 5.9, 1.7 Hz, 2H, -OCH2CH2CH2NHCbz), 3.40 (t, J = 6.3 Hz, 2H, - OCH2CH2CH2NHCbz), 1.98 (p, J = 5.9 Hz, 2H, -OCH2CH2CH2NHCbz).13C NMR (75 MHz, CDCl3) δ 156.7, 156.6 (C=O Cbz, CAr-O), 136.6, 129.3, 129.0, 128.5, 128.09, 128.04, 120.7, 111.0 (C-Ar), 66.7 (OCH2), 65.7 (OCH2), 61.5 (OCH2), 38.6 (CH2-NHCbz), 29.4 (- CH2- linker). LC-HRMS (ESI) calc. for C18H21NO4Na [M+Na]+: 338.1363; found: 338.1353. Step f Benzyl (3-(2-(bromomethyl)phenoxy)propyl)carbamate
In analogy to the procedure described in Example 1 f), benzyl (3-(2- (hydroxymethyl)phenoxy)propyl)carbamate was reacted to afford the title compound (2.00 g, 5.29 mmol, 80%). 1H NMR (300 MHz, CDCl3) δ 7.45 – 7.18 (m, 7H), 6.98 – 6.79 (m, 2H), 5.11 (s, 2H, OCH2), 4.54 (s, 2H, CH2-Br), 4.10 (t, J = 5.8 Hz, 2H, , OCH2 linker), 3.49 (q, J = 6.4 Hz, 2H, CH2-NHCbz), 2.18 – 1.96 (m, 2H , -CH2- linker).13C NMR (75 MHz, CDCl3) δ 156.8, 156.7 (C=O Cbz, CAr-O), 136.7, 131.0, 130.8, 130.5, 130.4, 128.7, 128.2, 126.2, 125.9, 121.0, 111.77, 111.71 (C-Ar), 66.8 (-OCH2-), 65.85 (-OCH2-), 42.13 (-CH2- NHCbz), 38.6 (CH2-Br), 29.53 (-CH2- linker). LC-HRMS (ESI) calc. for C18H21BrNO3 [M+H]+: 378.0699; found: 378.0700 Step g tert-Butyl 3-(((2-(3- (((benzyloxy)carbonyl)amino)propoxy)benzyl)oxy)methyl)azetidine-1-carboxylate In analogy to the procedure described in Example 1 g), benzyl (3-(2- (bromomethyl)phenoxy)propyl)carbamate was reacted with tert-butyl 3- (hydroxymethyl)azetidine-1-carboxylate (CAS RN 142253-56-3) to afford the title compound (401 mg, 0.83 mmol, 59%).1H NMR (300 MHz, CDCl3) δ 7.41 – 7.28 (m, 7H),
6.95 (td, J = 7.5, 1.1 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 5.46 (s, 1H, NHCbz), 5.10 (s, 2H, OCH2), 4.54 (s, 2H, OCH2), 4.05 (t, J = 5.8 Hz, 2H), 3.92 (t, J = 8.4 Hz, 2H), 3.67 – 3.51 (m, 4H), 3.43 (q, J = 6.1 Hz, 2H, CH2NHCbz), 2.81 – 2.63 (m, 1H, CH azetidine), 2.02 (p, J = 6.0 Hz, 2H, CH2 linker), 1.42 (s, 9H, 3 x CH3 Boc).13C NMR (75 MHz, CDCl3) δ 156.7, 156.6, 156.5 (C=O Cbz, C=O Boc, CAr-O), 136.8, 129.6, 129.2, 128.6, 128.2, 126.4, 120.8, 111.4, 79.4 (C(CH3)3 Boc), 72.4 (OCH2), 68.7 (OCH2), 66.7 (OCH2), 66.4 (OCH2), 52.0 (2 x N-CH2- azetidine), 39.1 (CH2NHCbz), 29.6(CH azetidine), 28.5 (3 x CH3 Boc), 27.1 (- CH2- linker). LC-HRMS (ESI) calc. for C27H37N2O6 [M+H]+: 485.2646; found: 485.2646. BB9 tert-Butyl 3-(((2-((5- (((benzyloxy)carbonyl)amino)pentyl)oxy)benzyl)oxy)methyl)azetidine-1-carboxylate
Step d Ethyl 2-((5-(((benzyloxy)carbonyl)amino)pentyl)oxy)benzoate
In analogy to the procedure described in Example 1g), ethyl salicylate (CAS RN 118-61-6) was reacted with 5-(((benzyloxy)carbonyl)amino)pentyl 4-methylbenzenesulfonate (CAS RN 93066-51-4) to afford the title compound (1.0 g, 2.59 mmol, 89%). 1H NMR (300 MHz, CDCl3) δ 7.77 (dd, J = 7.7, 1.8 Hz, 1H), 7.52 – 7.28 (m, 6H), 7.04 – 6.84 (m, 2H), 5.09 (s, 2H, O-CH2), 4.31 (q, J = 7.1 Hz, 2H, O-CH2-CH3), 4.02 (t, J = 6.2 Hz, 2H, O-CH2), 3.23 (m, 2H, -CH2-NHCbz), 1.84 (p, J = 6.5 Hz, 2H, -CH2- alkane), 1.64 – 1.53 (m, 4H, 2 x - CH2- alkane), 1.33 (t, J = 7.1 Hz, 3H, O-CH2-CH3). 13C NMR (75 MHz, CDCl3) δ 166.6, 158.6, 156.6 (C=O CO2Et, C=O Cbz, CAr-O), 136.8, 133.4, 131.66, 128.6, 128.22, 128.19, 120.8, 120.3, 113.2 (C-Ar), 68.5, 66.7, 60.9 (3 x O-CH2), 41.0 (-CH2-NHCbz), 31.1, 28.8, 23.2 (3 x CH2 alkane), 14.44 (O-CH2CH3). LC-HRMS (ESI) calc. for C22H27NO5Na [M+Na]+: 408.1781; found: 408.1798. Step e Benzyl (5-(2-(hydroxymethyl)phenoxy)pentyl)carbamate
In analogy to the procedure described in Example 1 e), ethyl 2-((5- (((benzyloxy)carbonyl)amino)pentyl)oxy)benzoate was reacted to afford the title compound
(737 mg, 2.15 mmol, 86%).1H NMR (300 MHz, CDCl3) δ 7.41 – 7.19 (m, 7H), 6.93 (td, J = 7.4, 1.0 Hz, 1H), 5.10 (s, 2H, OCH2), 4.68 (s, 2H, OCH2), 4.01 (t, J = 6.3 Hz, 2H, OCH2), 3.23 (t, J = 6.6 Hz, 2H CH2NHCbz), 1.84 (p, J = 6.5 Hz, 2H, -CH2- alkane), 1.68 – 1.46 (m, 4H, 2 x -CH2- alkane).13C NMR (75 MHz, CDCl3) δ 157.0, 156.6 (C=O Cbz, CAr-O), 136.7, 129.3, 129.1, 128.9, 128.7, 128.3, 128.3, 120.8, 111.2, 67.7 (OCH2), 66.8 (OCH2), 62.3 (CH2OH), 41.0 (CH2NHCbz), 29.9 (-CH2- alkane), 27.1 (-CH2- alkane), 23.5 (-CH2- alkane). LC-HRMS (ESI) calc. for C20H25NO4Na [M+Na]+: 366.1676; found: 366.1691. Step f tert-Butyl 3-(((2-((5- (((benzyloxy)carbonyl)amino)pentyl)oxy)benzyl)oxy)methyl)azetidine-1-carboxylate In analogy to the procedure described in Example 1 f), benzyl (5-(2- (hydroxymethyl)phenoxy)pentyl)carbamate was reacted with tert-butyl 3- (hydroxymethyl)azetidine-1-carboxylate (CAS RN 142253-56-3) to afford the title compound 67.6 mg, 0.132 mmol, 53%) was obtained.1H NMR (600 MHz, CDCl3) δ 7.38 – 7.28 (m, 5H), 7.27 – 7.19 (m, 2H), 6.94 (t, J = 7.4 Hz, 1H), 6.84 (d, J = 8.3 Hz, 1H), 5.10 (s, 2H, OCH2), 4.97 (s, 1H, NHCbz), 4.56 (s, 2H, OCH2), 4.00 – 3.93 (m, 4H), 3.70 – 3.64 (m, 2H), 3.64 – 3.59 (m, 2H), 3.23 (q, J = 6.7 Hz, 2H, CH2NHCbz), 2.82 – 2.73 (m, 1H, CH azetidine), 1.85 – 1.77 (m, 2H, CH2 linker), 1.63 – 1.48 (m, 4H, CH2 linker), 1.43 (s, 9H, 3 x CH3 Boc).13C NMR (151 MHz, CDCl3) δ 156.63, 156.58, 156.55 (C=O Boc, C=O Cbz, CAr-O), 136.8, 129.1, 128.9, 128.6, 128.21, 128.17, 126.7, 120.5, 111.2, 79.4 (C(CH3)3 Boc), 72.6, 68.2, 67.8, 66.7 (4 x OCH2), 52.0 (2 x NCH2 azetidine), 41.1 (CH2NHCbz), 29.8, 29.0, 28.8 (CH azetidine, 2 x CH2 linker), 28.5 (3 x CH3 Boc), 23.5 (CH2 linker). LC-HRMS (ESI) Calc for C29H40N2O6Na [M+Na]+: 535.2779; found: 537.2784 BB10 tert-Butyl 6-(2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzylidene)-2- azaspiro[3.3]heptane-2-carboxylate
Step i Synthesis of the building block: tert-butyl 6-((4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)methylene)-2-azaspiro[3.3]heptane-2-carboxylate
In an oven-dried flask, tetramethylpiperidine (CAS RN 768-66-1,1.25 mL, 7.40 mmol) was dissolved in anhydrous THF (37.0 mL) and cooled to -78 °C under N2 atmosphere. A solution of nBuLi 2.5 M in THF (3.00 mL, 7.40 mmoL) was added dropwise, and the reaction was stirred at the same temperature for 30 min. Next, a 0.84 M solution of bis((pinacolato)boryl)methane (CAS RN 78782-17-9) in THF (8.83 mL, 7.40 mmol) was added dropwise. The reaction was stirred for 5 min and then a 0.20 M solution of ketone in anhydrous THF (18.5 mL, 3.70 mmol) was added dropwise over 5 min. The reaction mixture was slowly allowed to warm up to room temperature overnight. Upon completion, the reaction was opened to air and filtered through a silica plug eluting with Et2O. The mixture was concentrated under reduced pressure and purified by silica gel chromatography 0 to 20% EtOAc in cyclohexane with ELSD detection to afford the title compound in quantitative yield. LC-HRMS (ESI) calc. for C18H31BNO4 [M+H]+: 336.2340; found: 336.2342. Step d Benzyl (2-(2-bromophenoxy)ethyl)carbamate
In analogy to the procedure described in Example 1 d), 2-bromophenol (CAS 95-56-7) was reacted with 2-(((benzyloxy)carbonyl)amino)ethyl 4-methylbenzenesulfonate (CAS RN 93407-96-6) to afford the title compound (985 mg, 2.81 mmol, 94%).1H NMR (300 MHz, CDCl3) δ 7.47 (dd, J = 7.9, 1.6 Hz, 1H), 7.33 – 7.13 (m, 6H), 6.87 – 6.73 (m, 2H), 5.31 (s, 1H, NHCbz), 5.06 (s, 2H, OCH2), 4.03 (t, J = 5.0 Hz, 2H, OCH2), 3.59 (q, J = 5.4 Hz, 2H, CH2NHCbz).13C NMR (75 MHz, CDCl3) δ 156.6, 154.9 (C=O Cbz, CAr-O), 136.5, 133.5, 128.7, 128.7, 128.29, 128.26, 122.6, 113.7, 112.5, 68.5 (OCH2), 67.0 (OCH2), 40.6 (CH2NHCbz). LC-HRMS (ESI) Calc for C16H16BrNO3Na [M+Na]+: 372.0206; found: 372.0209. Step h tert-Butyl 6-(2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzylidene)-2- azaspiro[3.3]heptane-2-carboxylate In a closed vial under nitrogen atmosphere, tert-butyl 6-((4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)methylene)-2-azaspiro[3.3]heptane-2-carboxylate (117 mg, 0.35 mmol),
Benzyl (2-(2-bromophenoxy)ethyl)carbamate (123 mg, 0.35 mmol) and Na2CO3 (74.2 mg, 0.70 mmol) were suspended in a dioxane/water 3:1 mixture (2.30 mL) previously purged by bubbling N2 with sonication. The mixture was purged with N2 bubbling for 10 min. Then, Pd(dppf)Cl2 (CAS RN 72287-26-4) was added and the mixture was purged for additional 15 min. The reaction was warmed up to 55 °C and stirred overnight at this temperature. The reaction was then diluted with DCM (15 mL), extracted with aq. sat. NaHCO3 (20 mL) and washed with brine (20 mL). The organic layer was dried over MgSO4, concentrated under reduced pressure and purified by silica gel chromatography 0 to 60% EtOAc in cyclohexane to afford the title compound (97.0 mg, 0.20 mmol, 58%). LC-HRMS (ESI) calc. for C28H34N2O5Na [M+Na]+: 501.2360; found: 501.2388. BB11 tert-Butyl 6-(3-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzylidene)-2- azaspiro[3.3]heptane-2-carboxylate
Step d Benzyl (2-(3-bromophenoxy)ethyl)carbamate
In analogy to the procedure described for BB10, step d), 3-Bromophenol (CAS RN 591-20- 8) was reacted with 2-(((benzyloxy)carbonyl)amino)ethyl 4-methylbenzenesulfonate (CAS RN 93407-96-6) to afford the title compound (366mg, 0.69mmol, 69%). LC-MS [M+Na]+: 372.0. Step h tert-Butyl 6-(3-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzylidene)-2- azaspiro[3.3]heptane-2-carboxylate In analogy to the procedure described for BB10, step h), Benzyl (2-(3- bromophenoxy)ethyl)carbamate was reacted with tert-butyl 6-((4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)methylene)-2-azaspiro[3.3]heptane-2-carboxylate to afford the title compound (181mg, 0.38mmol, 63%). 1H NMR (300 MHz, CDCl3) δ 7.41 – 7.30 (m, 5H), 7.21 (t, J = 8.1 Hz, 1H), 6.83 – 6.60 (m, 3H), 6.11 (s, 1H), 5.22 (s, 1H), 5.11 (s, 2H), 4.08 –
3.90 (m, 6H), 3.60 (d, J = 5.5 Hz, 2H), 3.20 (s, 2H), 3.04 (s, 2H), 1.42 (s, 9H). LC-MS (ESI): [M+H]+: 479.2. BB12 tert-Butyl 6-(2-((5-(((benzyloxy)carbonyl)amino)pentyl)oxy)benzylidene)-2- azaspiro[3.3]heptane-2-carboxylate
Step d Benzyl (5-(2-bromophenoxy)pentyl)carbamate
In analogy to the procedure described for BB10, step d), 3-Bromophenol (CAS RN 591-20- 8) was reacted with 5-(((benzyloxy)carbonyl)amino)pentyl 4-methylbenzenesulfonate (CAS RN 93066-51-4) to afford the title compound (403 mg, 1.03 mmol, 51%). 1H NMR (300 MHz, CDCl3) δ 7.52 (dd, J = 7.9, 1.6 Hz, 1H), 7.39 – 7.20 (m, 6H), 6.94 – 6.71 (m, 2H), 5.10 (s, 2H, OCH2), 4.78 (s, 1H, NHCbz), 4.01 (t, J = 6.2 Hz, 2H, OCH2), 3.24 (q, J = 6.3 Hz, 2H, CH2NHCbz), 1.86 (t, J = 6.8 Hz, 2H, CH2 linker), 1.76 – 1.48 (m, 4H, 2 x CH2 linker).13C NMR (75 MHz, CDCl3) δ 156.4, 155.3 (C=O Cbz, CAr-O), 136.6, 133.3, 128.5, 128.4, 128.1, 121.8, 113.2, 112.3, 68.8 (OCH2), 66.7 (OCH2), 41.0 (CH2NHCbz), 29.7 (CH2 linker), 28.7 (CH2 linker), 23.3 (CH2 linker). LC-HRMS (ESI) calc. for C19H23BrNO3 [M+H]+: 392.0856; found: 392.0860. Step h tert-Butyl 6-(2-((5-(((benzyloxy)carbonyl)amino)pentyl)oxy)benzylidene)-2- azaspiro[3.3]heptane-2-carboxylate In analogy to the procedure described for BB10, step h), Benzyl (5-(2- bromophenoxy)pentyl)carbamate was reacted with tert-butyl 6-((4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)methylene)-2-azaspiro[3.3]heptane-2-carboxylate to afford the title compound (100 mg, 0.19 mmol, 25%). LC-HRMS (ESI) calc. for C31H41N2O5 [M+H]+: 521.3010; found: 521.3000. BB 14 tert-Butyl (1R,5S)-6-(((2-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzyl)oxy)methyl)- 3-azabicyclo[3.1.0]hexane-3-carboxylate
In analogy to the procedure described in Example 1 g), benzyl (2-(2- (bromomethyl)phenoxy)ethyl)carbamate (see Example 1) was reacted with tert-butyl (1R,5S,6r)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (CAS RN 827599- 21-3) to afford the title compound (32.3 mg, 0.069 mmol, 57%).1H NMR (300 MHz, CDCl3) δ 7.40 – 7.20 (m, 7H), 6.96 (td, J = 7.5, 1.1 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 5.09 (s, 2H, - OCH2-), 4.52 (s, 2H, -OCH2-), 4.10 (t, J = 5.1 Hz, 2H), 3.65 – 3.39 (m, 5H), 3.36 – 3.19 (m, 3H), 1.49 – 1.32 (m, 11H, 3 x CH3 Boc, 2 x CH fused cycle), 0.98 – 0.87 (m, 1H, CH propyl cycle).13C NMR (75 MHz, CDCl3) δ 156.57, 156.53, 155.0 (C=O Cbz, C=O Boc, CAr-O), 136.6, 129.8, 129.2, 128.6, 128.30, 128.25, 127.0, 121.2, 112.2 (C-Ar), 79.4, 71.7, 68.0, 67.6, 66.9, 48.1 (CH cyclopropyl), 40.7 (CH2-NHCbz), 28.6 (3 x CH3 Boc), 27.0, 22.4 (CH fused cycle). LC-HRMS (ESI) calc. for C28H37N2O6 [M+H]+: 497.2646; found: 497.2658. BB16 tert-Butyl 3-(3-(ethoxycarbonyl)phenoxy)azetidine-1-carboxylate
In analogy to the procedure described in Example 39 d), ethyl 3-hydroxy benzoate (CAS RN 7781-98-8) was reacted with tert-butyl 3-iodoazetidine-1-carboxylate (CAS RN 254454-54-1) to afford the title compound. LC-MS (ESI) [M+Na]+: 344.1. BB17 tert-Butyl 3-((2-(ethoxycarbonyl)phenoxy)methyl)azetidine-1-carboxylate
In analogy to the procedure described in Example 39 d), ethyl 3-hydroxy benzoate (CAS RN 7781-98-8) was reacted with tert-butyl 3-(bromomethyl)azetidine-1-carboxylate (CAS RN 253176-93-1) to afford the title compound. LC-MS (ESI) [M+Na]+: 358.1.
Claims
CLAIMS 1. A compound of formula (I) or (II)
or a pharmaceutically acceptable salt thereof, wherein: in Formula (I), R1 is selected from:
; wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I); in Formula (II), R1 is selected from:
wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (II); R2 is selected from:
, , , p p , , and ; wherein: a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1 or 2; V is selected from hydrogen and methyl; ,
Ar is C6-C10-aryl or 5- to 14-membered heteroaryl; X is selected from O, S, Si(CH3)2, and CH2; and Y is selected from OH, NH2, N(CH3)2, N(CD3)2, and azetidin-1-yl;
R3 is selected from hydrogen, C1-C6-alkoxycarbonyl and C1-C6-alkoxycarbonyl- NH-C1-C6-alkyl-NH-C(O)–;
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I) or (II), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I) or (II); and n is an integer selected from 1, 2, 3 and 4. 2. The compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from:
wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I).
3. The compound of formula (I) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein A is:
(i) X is CH; and L is selected from –CH2– and –CH2O–; or
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I). 4. The compound of formula (I) according to claim 3, or a pharmaceutically acceptable salt thereof, wherein A is:
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points
of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I). 5. The compound of formula (I) according to claim 4, or a pharmaceutically acceptable salt thereof, wherein A is:
X is CH; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I). 6. The compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein: R2 is selected from: ,
a wavy line indicates the point of attachment of R2 to the remainder of formula (I);
p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; and n is an integer selected from 1, 2, and 4. 7. The compound of formula (I) according to claim 6, or a pharmaceutically acceptable salt thereof, wherein: R2 is selected from:
a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; and n is an integer selected from 1, 2, and 4. 8. The compound of formula (I) according to claim 7, or a pharmaceutically acceptable salt thereof, wherein: R2 is selected from:
, , , and p ; wherein: a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; and n is an integer selected from 1 and 4. 9. The compound of formula (II) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein A is:
(i) and L is selected from –OCH2–, –CH2OCH2–, and –O–; or
(ii) and L is –CH2O–; wherein X is CH; wherein a wavy line indicates the point of attachment to L; and an asterisk indicates the point of attachment to the carbonyl group of formula (II). 10. The compound of formula (I) according to claim 1, wherein:
R1 is selected from:
wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I); R2 is selected from: ,
a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; A is:
(i) , or ; and L is selected from –CH2O–, –OCH2–, –CH2OCH2–, and –O–; or (ii) or ; wherein (i) X is CH; and L is selected from –CH2– and –CH2O–; or
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A; wherein a wavy line indicates the point of attachment to L; and an asterisk indicates the point of attachment to the carbonyl group of formula (I); and n is an integer selected from 1, 2, and 4. 11. The compound of formula (I) according to claim 10, wherein: R1 is selected from:
wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I); R2 is selected from:
, , , and p ; wherein: a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2;
(ii) X and L, taken together, form a group , wherein the wavy line indicates the point of attachment of L to the phenyl moiety within formula (I), and the two asterisks indicate the points of attachment of X to the respective neighbouring atoms within ring A;
wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I); and n is an integer selected from 1, 2, and 4. 12. The compound of formula (I) according to claim 11, wherein: R1 is selected from:
wherein a wavy line indicates the point of attachment of R1 to the remainder of formula (I); R2 is selected from:
a wavy line indicates the point of attachment of R2 to the remainder of formula (I); p is 1; V is methyl; W is methyl X is selected from O and Si(CH3)2; and Y is N(CH3)2; A is:
(i) and L is –CH2OCH2–; or (ii) and L is –CH2–; wherein X is CH; wherein a wavy line indicates the point of attachment of A to L; and an asterisk indicates the point of attachment of A to the carbonyl group of formula (I); and n is an integer selected from 1 and 4. The compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) or (II) is selected from: benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-2-azaspiro[3.3]heptan-6-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-2-azaspiro[3.5]nonan-7-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-(((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-2-azaspiro[3.3]heptan-6-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (3-(3-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)propyl)carbamate; benzyl (6-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)hexyl)carbamate; benzyl (2-(2-(((1-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate;
cyclohex-1-en-1-ylmethyl (2-(2-((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3- b][1,4]oxazine-6-carbonyl)-2-azaspiro[3.3]heptan-6- ylidene)methyl)phenoxy)ethyl)carbamate; benzyl (2-(3-((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-2-azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((7-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)-7-azaspiro[3.5]nonan-2-yl)oxy)methyl)phenoxy)ethyl)carbamate; benzyl (5-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-ylidene)methyl)phenoxy)pentyl)carbamate; benzyl (2-(2-((((1R,5S)-3-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3- b][1,4]oxazine-6-carbonyl)-3-azabicyclo[3.1.0]hexan-6- yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (R)-(2-(2-(((1-(3-(2-oxooxazolidin-4-yl)propanoyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamate; benzyl (2-(2-(((1-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonyl)azetidin- 3-yl)methoxy)methyl)phenoxy)ethyl)carbamate; 2-(6-(2-(2-((7-nitro-1l2,3l2-benzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)benzyl)-2- azaspiro[3.3]heptane-2-carbonyl)-7-oxa-2,5-diazaspiro[3.4]octan-6-one; (4aR,8aS)-6-(3-(((2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4- yl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one; 2-(3-(((2-(2-((7-nitro-1H-3l2-benzo[c][1,2,5]oxadiazol-4- yl)amino)ethoxy)benzyl)oxy)methyl)azetidine-1-carbonyl)-7-oxa-2,5- diazaspiro[3.4]octan-6-one; (4aR,8aS)-6-(3-(((2-(3-((7-nitrobenzo[c][1,2,5]oxadiazol-4- yl)amino)propoxy)benzyl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(3-(((2-((5-((7-nitro-1,3-dihydrobenzo[c][1,2,5]oxadiazol-4- yl)amino)pentyl)oxy)benzyl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(6-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)benzyl)- 2-azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin- 3(4H)-one; (4aR,8aS)-6-(6-(3-(2-((7-nitro-1,3-dihydrobenzo[c][1,2,5]oxadiazol-4- yl)amino)ethoxy)benzyl)-2-azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one; 2-(7-(Dimethylamino)-3-(dimethyliminio)-5,5-dimethyl-3,5- dihydrodibenzo[b,e]silin-10-yl)-4-((5-(2-((2-(6-oxo-7-oxa-2,5- diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)pentyl)carbamoyl)benzoate; 3,3-dimethyl-1-(6-oxo-6-((2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2- carbonyl)-2-azaspiro[3.3]heptan-6-yl)methyl)phenoxy)ethyl)amino)hexyl)-2-((E)- 3-((Z)-1,3,3-trimethylindolin-2-ylidene)prop-1-en-1-yl)-3H-indol-1-ium 2,2,2- trifluoroacetate; 3-(5,5-difluoro-7,9-dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin- 3-yl)-N-(2-(2-((2-(6-oxo-7-oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2- azaspiro[3.3]heptan-6-yl)methyl)phenoxy)ethyl)propanamide; 2,2,2-trifluoroacetic acid, 3,3-dimethyl-1-(6-oxo-6-((2-(2-(((1-((4aR,8aS)-3- oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)amino)hexyl)-2-((E)-3-((Z)-1,3,3- trimethylindolin-2-ylidene)prop-1-en-1-yl)-3H-indol-1-ium salt; 3,3-dimethyl-1-(6-oxo-6-((2-(2-((2-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3- b][1,4]oxazine-6-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)ethyl)amino)hexyl)-2-((E)-3-((Z)-1,3,3-trimethylindolin-2- ylidene)prop-1-en-1-yl)-3H-indol-1-ium 2,2,2-trifluoroacetate; 3-(5,5-difluoro-7,9-dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin- 3-yl)-N-(2-(2-(((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)methyl)phenoxy)ethyl)propanamide; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((2-(2-(((1- ((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamoyl)benzoate and 2-(6- (dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((2-(2-(((1-((4aR,8aS)- 3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamoyl)benzoate;
2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((2-(2-(((1- ((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)ethyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((3-(2-(((1- ((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)propyl)carbamoyl)benzoate and 2-(6- (dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((3-(2-(((1-((4aR,8aS)- 3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)propyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((3-(2-(((1- ((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)propyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((5-(2-((2-(6-oxo-7- oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)pentyl)carbamoyl)benzoate compound and 2-(6- (dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((5-(2-((2-(6-oxo-7- oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)pentyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((5-(2-((2-(6-oxo-7- oxa-2,5-diazaspiro[3.4]octane-2-carbonyl)-2-azaspiro[3.3]heptan-6- yl)methyl)phenoxy)pentyl)carbamoyl)benzoate; 2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-4-((5-(2-(((1- ((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)pentyl)carbamoyl)benzoate and 2-(6- (dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-((5-(2-(((1-((4aR,8aS)- 3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3- yl)methoxy)methyl)phenoxy)pentyl)carbamoyl)benzoate; ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)benzoate; ethyl 3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)benzoate; ethyl 2-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)benzoate;
tert-Butyl (2-(3-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)oxy)benzamido)ethyl)carbamate; tert-butyl (2-(2-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6- carbonyl)azetidin-3-yl)methoxy)benzamido)ethyl)carbamate; (4aR,8aS)-6-(3-((benzyloxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(6-(benzyloxy)-2-azaspiro[3.3]heptane-2-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one; and (4aR,8aS)-6-(3-(phenoxymethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one. 14. Use of a compound of formula (II) according to any one of claims 1, 2, 9 and 13 in the manufacture of a compound of formula (I) according to any one of claims 1 to 8 and 10 to 13. 15. A process of manufacturing the compounds of formula (I) according to any one of claims 1 to 8 and 10 to 13, comprising reacting an amine 4,
wherein A, L, R1, and n are as defined in claim 1, with: (a) a fluorescent label containing a carboxylic acid moiety in the presence of a coupling reagent and a base; or (b) a fluorescent label containing an N-hydroxisuccinimide (NHS) activated ester in the presence of a base; or (c) 4-chloro-7-nitrobenz-2-oxa-1,3-diazole or 4-fluoro-7-nitrobenz-2-oxa-1,3- diazole in in the presence of a base; to afford said compound of formula (I). 16. A compound of formula (I) according to any one of claims 1 to 8 and 10 to 13, when manufactured according to the process of claim 15.
17. A compound of formula (I) according to any one of claims 1 to 8 and 10 to 13, for use in monoacylglycerol lipase (MAGL) occupancy studies. 18. A compound of formula (I) according to any one of claims 1 to 8 and 10 to 13, for use in diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal. 19. A compound of formula (I) according to any one of claims 1 to 8 and 10 to 13, for use in generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data. 20. Use of a compound of formula (I) according to any one of claims 1 to 8 and 10 to 13 in monoacylglycerol lipase (MAGL) occupancy studies. 21. Use of a compound of formula (I) according to any one of claims 1 to 8 and 10 to 13 in diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal. 22. Use of a compound of formula (I) according to any one of claims 1 to 8 and 10 to 13 for generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data. 23. A method of studying monoacylglycerol lipase (MAGL) occupancy, comprising contacting MAGL with a compound of formula (I) according to any one of claims 1 to 8 and 10 to 13. 24. A method of diagnostic imaging of monoacylglycerol lipase (MAGL) in a mammal, comprising contacting MAGL with a compound of formula (I) according to any one of claims 1 to 8 and 10 to 13. 25. A method of generating monoacylglycerol lipase (MAGL) equilibrium and kinetic binding data, comprising contacting MAGL with a compound of formula (I) according to any one of claims 1 to 8 and 10 to 13. 26. The invention as described hereinbefore.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22196439 | 2022-09-20 | ||
EP22196439.8 | 2022-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024061853A1 true WO2024061853A1 (en) | 2024-03-28 |
Family
ID=83398393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/075703 WO2024061853A1 (en) | 2022-09-20 | 2023-09-19 | Fluorescent probes for magl |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024061853A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3279191A1 (en) * | 2015-03-30 | 2018-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2019180185A1 (en) * | 2018-03-22 | 2019-09-26 | F. Hoffmann-La Roche Ag | Oxazine monoacylglycerol lipase (magl) inhibitors |
WO2020104494A1 (en) * | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
-
2023
- 2023-09-19 WO PCT/EP2023/075703 patent/WO2024061853A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3279191A1 (en) * | 2015-03-30 | 2018-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2019180185A1 (en) * | 2018-03-22 | 2019-09-26 | F. Hoffmann-La Roche Ag | Oxazine monoacylglycerol lipase (magl) inhibitors |
WO2020104494A1 (en) * | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
Non-Patent Citations (10)
Title |
---|
A. J. VERNALLS. J. HILLB. KELLAM, BR. J. PHARMACOL., vol. 171, 2014, pages 1073 - 1084 |
BARANYR. B. MERRIFIELD, J. AM. CHEM. SOC., vol. 99, 1977, pages 7363 |
C. ILIOPOULOS-TSOUTSOUVASR. N. KULKARNIA. MAKRIYANNISS. P. NIKAS, EXPERT OPIN. DRUG DISCOV., vol. 13, 2018, pages 933 - 947 |
CAS, no. 1363383-18-9 |
G. SARTORI ET AL., GREEN CHEMISTRY, vol. 2, 2000, pages 140 |
H. WALDMANN ET AL., ANGEW. CHEM., vol. 35, 1996, pages 2056 |
KOVALENKO ET AL.: "The Boron-Wittig Olefination of Aldehydes and Ketones with Bis[(pinacolato)boryl]methane: an Extended Reaction Scope", EUR J. ORG. CHEM., 2019, pages 5264 - 5635 |
L. A. STODDARTL. E. KILPATRICKS. J. BRIDDONS. J. HILL, NEUROPHARMACOLOGY, vol. 98, 2015, pages 48 - 57 |
RICHARD C. LAROCK: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 1999, JOHN WILEY & SONS |
T. W. GREENEP. G. M. WUTTS: "Protective Groups in Organic Chemistry", 2006, JOHN WILEY & SONS |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7553450B2 (en) | Compositions for inhibiting ubiquitin-specific protease 1 | |
ES2895385T3 (en) | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | |
TWI825227B (en) | New heterocyclic compounds | |
ES2728353T3 (en) | Compound of (6S, 9aS) -N-benzyl-6 - [(4-hydroxyphenyl) methyl] -4,7-dioxo-8 - ({6- [3- (piperazin-1-yl) azetidin-1-yl ] pyridin-2-yl} methyl) -2- (prop-2-en-1-yl) -octahydro-1H-pyrazino [2,1-c] [1,2,4] triazin-1-carboxamide | |
ES2390042T3 (en) | Novel intermediates useful for the preparation of alpha- (N-sulfonamido) acetamide compounds | |
DK2861566T3 (en) | NEW DIAZASPIROCYCLOALKANES AND AZASPIROCYCLOALKANES | |
ES2785498T3 (en) | Phthalazinones and isoquinolinones as ROCK inhibitors | |
JP5583694B2 (en) | Pyrrolidine compounds that modulate the CB2 receptor | |
ES2733096T3 (en) | Intermediaries for the synthesis of cyclic P1 linkers as XIA factor inhibitors | |
ES2376278T3 (en) | HYDROXIMETHYL PIRROLIDINS AS AGENISTS OF THE BETA 3 ADRENERGIC RECEIVER. | |
US20220220373A1 (en) | Fluorescent probes for monoacylglycerol lipase (magl) | |
ES2452550T3 (en) | Derivatives of (uncle) morpholine as modulators of S1P | |
US20110230493A1 (en) | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | |
EA027113B1 (en) | Complement pathway modulators and uses thereof | |
CA2587360A1 (en) | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
EA036137B1 (en) | Tetrahydroisoquinoline derivatives | |
JP2023507138A (en) | benzimidazole derivative | |
ES2544086T3 (en) | 2-Methoxy-pyridin-4-yl derivatives | |
WO2024061853A1 (en) | Fluorescent probes for magl | |
CN101823987A (en) | New DPP-IV inhibitors and preparation method and application thereof | |
TW202039494A (en) | Macrocyclic compound and use thereof | |
JP2022511167A (en) | Bicyclic heterocyclic derivative with selective BACE1 inhibitory activity | |
MXPA02001944A (en) | Synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates. | |
EP4267555A1 (en) | Octahydroisoquinolinyl derivatives | |
WO2023247666A1 (en) | Fluorescent probes for magl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23772503 Country of ref document: EP Kind code of ref document: A1 |